| 1 |
Di Nardo M, MacLaren G, Schellongowski P, Azoulay E, DeZern AE, Gutierrez C, Antonelli M, Antonini MV, Beutel G, Combes A, Diaz R, Fawzy Hassan I, Fowles JA, Jeong IS, Kochanek M, Liebregts T, Lueck C, Moody K, Moore JA, Munshi L, Paden M, Pène F, Puxty K, Schmidt M, Staudacher D, Staudinger T, Stemmler J, Stephens RS, Vande Vusse L, Wohlfarth P, Lorusso R, Amodeo A, Mahadeo KM, Brodie D; European Society of Intensive Care Medicine, the International ECMO Network, and the Extracorporeal Life Support Organization. Extracorporeal membrane oxygenation in adults receiving haematopoietic cell transplantation: an international expert statement. Lancet Respir Med 2023:S2213-2600(22)00535-5. [PMID: 36924784 DOI: 10.1016/S2213-2600(22)00535-5] [Reference Citation Analysis]
|
| 2 |
Morita-Fujita M, Shindo T, Iemura T, Arai Y, Kanda J, Okada K, Ueda Y, Yoshiyuki O, Anzai N, Mori T, Ishikawa T, Otsuka Y, Yonezawa A, Yuhi N, Imada K, Oba A, Itoh M, Okamoto Y, Kitano T, Ikeda T, Kotani S, Akasaka T, Yago K, Watanabe M, Nohgawa M, Tsuji M, Takeoka T, Yamamoto R, Arima N, Yoshinaga N, Hishizawa M, Yamashita K, Kondo T, Takaori-Kondo A; Kyoto Stem Cell Transplantation Group (KSCTG). Epitope mismatch at HLA-DRB1 associates with reduced relapse risk in cord blood transplant for standard-risk hematological malignancy. Transplant Cell Ther 2023:S2666-6367(23)01136-3. [PMID: 36889508 DOI: 10.1016/j.jtct.2023.03.002] [Reference Citation Analysis]
|
| 3 |
Blennerhassett R, Othman J, Biscoe A, Kliman D, Mills G, Blyth E, Micklethwaite K, Kwan J, Bilmon I, Bhattacharyya A, Panicker S, Fay K, Milliken S, Ma D, Hamad N, Stevenson W, Arthur C, Moore J, Greenwood M, Gottlieb D, Kerridge I. Long-term outcomes of corticosteroid graft versus host disease prophylaxis in peripheral blood allogeneic haemopoietic stem cell transplant: a comparative cohort analysis. Intern Med J 2023. [PMID: 36878730 DOI: 10.1111/imj.16043] [Reference Citation Analysis]
|
| 4 |
Thornton CP, Bandeen-Roche K, Dolinar M, Roberts Lavigne LC, George Lansey D, Jones R, Walston J, Varadhan R, Hladek M, Imus P. Clinical trial participation predicts improved survival in older adults receiving allogeneic blood and marrow transplant. BMC Geriatr 2023;23:120. [PMID: 36869287 DOI: 10.1186/s12877-023-03803-7] [Reference Citation Analysis]
|
| 5 |
Malkan ÜY, Göker H, Demiroğlu H, Tekin F, Akdemir NB, Karakulak EA, Sayınalp N, Haznedaroğlu İC, Özcebe Oİ, Büyükaşık Y. A single-center experience of haploidentical stem cell transplantation in hematological malignancies. Turk J Med Sci 2023;53:352-9. [PMID: 36945951 DOI: 10.55730/1300-0144.5591] [Reference Citation Analysis]
|
| 6 |
Wang K, Jian X, Xu Z, Wang H. Pre-transplant CRP-albumin ratio as a biomarker in patients receiving haploidentical allogeneic hematopoietic transplantation: Developing a novel DRCI-based nomogram. Front Immunol 2023;14:1128982. [PMID: 36875097 DOI: 10.3389/fimmu.2023.1128982] [Reference Citation Analysis]
|
| 7 |
Fan S, Pan TZ, Dou LP, Zhao YM, Zhang XH, Xu LP, Wang Y, Huang XJ, Mo XD. Preemptive interferon-α therapy could prevent relapse of acute myeloid leukemia following allogeneic hematopoietic stem cell transplantation: A real-world analysis. Front Immunol 2023;14:1091014. [PMID: 36817493 DOI: 10.3389/fimmu.2023.1091014] [Reference Citation Analysis]
|
| 8 |
Li T, He Q, Yang J, Cai Y, Huang C, Xu X, Qiu H, Niu J, Zhou K, Zhang Y, Xia X, Wei Y, Shen C, Ding X, Tong Y, Wan L, Song X. Low-Dose Anti-Thymocyte Globulin Plus Low-Dose Posttransplant Cyclophosphamide as an Effective Regimen for Prophylaxis of Graft Versus Host Disease After Haploidentical Peripheral Blood Stem Cell Transplantation With Maternal/Collateral Related Donors. Cell Transplant 2022;31:9636897221139103. [PMID: 36433646 DOI: 10.1177/09636897221139103] [Reference Citation Analysis]
|
| 9 |
Cao W, Li X, Zhang R, Bian Z, Zhang S, Li L, Xing H, Liu C, Xie X, Jiang Z, Fang X, Wan D, Yu J. Prognostic prediction of novel risk scores (AML-DRG and AML-HCT-CR) in acute myeloid leukemia patients with allogeneic hematopoietic stem cell transplantation. Sci Rep 2022;12:19024. [PMID: 36347881 DOI: 10.1038/s41598-022-20735-1] [Reference Citation Analysis]
|
| 10 |
Woelfinger P, Hauptrock B, Kriege O, List A, Schmitt T, Kuchen R, Theobald M, Wagner-Drouet EM. Pre-transplant platelet-to- lymphocyte ratio predicts outcome after allogeneic hematopoietic stem cell transplantation. Sci Rep 2022;12:18948. [PMID: 36347969 DOI: 10.1038/s41598-022-23344-0] [Reference Citation Analysis]
|
| 11 |
Shimada Y, Shiko Y, Hangaishi A, Kawasaki Y, Maruoka Y. Prolonged neutropenia is a risk of oral adverse events-related sepsis but is not associated with prognosis of tooth extraction in hematopoietic stem cell transplant recipients: a retrospective study. Journal of Oral and Maxillofacial Surgery, Medicine, and Pathology 2022. [DOI: 10.1016/j.ajoms.2022.09.002] [Reference Citation Analysis]
|
| 12 |
Lazzari L, Balaguer-Roselló A, Montoro J, Greco R, Hernani R, Lupo-Stanghellini MT, Villalba M, Giglio F, Facal A, Lorentino F, Guerreiro M, Bruno A, Pérez A, Xue E, Clerici D, Piemontese S, Piñana JL, Sanz MÁ, Solano C, de la Rubia J, Ciceri F, Peccatori J, Sanz J. Post-transplant cyclophosphamide and sirolimus based graft-versus-host disease prophylaxis after allogeneic stem cell transplantation for acute myeloid leukemia. Bone Marrow Transplant 2022. [PMID: 35680995 DOI: 10.1038/s41409-022-01725-3] [Reference Citation Analysis]
|
| 13 |
Berger M, Barone M, Spadea M, Saglio F, Pessolano R, Fagioli F. HSCT with mismatched unrelated donors: Bone marrow versus peripheral blood stem cells sources in pediatric patients. Pediatr Transplant 2022;26:e14233. [PMID: 35092128 DOI: 10.1111/petr.14233] [Reference Citation Analysis]
|
| 14 |
Teshigawara-Tanabe H, Hagihara M, Aoki J, Koyama S, Takahashi H, Nakajima Y, Kunimoto H, Tachibana T, Miyazaki T, Matsumoto K, Tanaka M, Yamazaki E, Fujisawa S, Kanamori H, Taguri M, Nakajima H. Clinical risk factors for patients with myelodysplastic syndromes undergoing allogeneic hematopoietic stem cell transplantation. Hematology 2022;27:620-8. [PMID: 35621915 DOI: 10.1080/16078454.2022.2052601] [Reference Citation Analysis]
|
| 15 |
de Lima VJT, da Silva AF, Kerbauy LN, Kerbauy MN, Lerner D, Colares M, Ribeiro AAF, da Silva CF, Hamerschlak N, Arcuri LJ. Risk factors for adverse outcomes following haploidentical hematopoietic cell transplantation with posttransplant cyclophosphamide: a two-center analysis. Ann Hematol 2022. [PMID: 35575911 DOI: 10.1007/s00277-022-04865-0] [Reference Citation Analysis]
|
| 16 |
Arcuri LJ, Lerner D, Tavares RCBDS. Lower levels of cyclosporine between days 0 and +21 may reduce later relapses without increasing graft-versus-host disease in children and adolescents with acute lymphoblastic leukemia who undergo myeloablative TBI-based allogeneic hematopoietic cell transplantation. Eur J Haematol 2022. [PMID: 35532300 DOI: 10.1111/ejh.13787] [Reference Citation Analysis]
|
| 17 |
Fattinger N, Roth JA, Baldomero H, Stolz D, Medinger M, Heim D, Tamm M, Halter JP, Passweg JR, Kleber M. External Validation of the Revised Pretransplant Assessment of Mortality Score in Allogeneic Hematopoietic Cell Transplantation: A Cohort Study. HemaSphere 2022;6:e704. [DOI: 10.1097/hs9.0000000000000704] [Reference Citation Analysis]
|
| 18 |
Saknite I, Patrinely JR, Zhao Z, Chen H, Beeghly-Fadiel A, Kim TK, Jagasia M, Byrne M, Tkaczyk ER. Association of Leukocyte Adhesion and Rolling in Skin With Patient Outcomes After Hematopoietic Cell Transplantation Using Noninvasive Reflectance Confocal Videomicroscopy. JAMA Dermatol 2022. [PMID: 35338704 DOI: 10.1001/jamadermatol.2022.0924] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 19 |
Berrien-Elliott MM, Foltz JA, Russler-Germain DA, Neal CC, Tran J, Gang M, Wong P, Fisk B, Cubitt CC, Marin ND, Zhou AY, Jacobs MT, Foster M, Schappe T, McClain E, Kersting-Schadek S, Desai S, Pence P, Becker-Hapak M, Eisele J, Mosior M, Marsala L, Griffith OL, Griffith M, Khan SM, Spencer DH, DiPersio JF, Romee R, Uy GL, Abboud CN, Ghobadi A, Westervelt P, Stockerl-Goldstein K, Schroeder MA, Wan F, Lie WR, Soon-Shiong P, Petti AA, Cashen AF, Fehniger TA. Hematopoietic cell transplantation donor-derived memory-like NK cells functionally persist after transfer into patients with leukemia. Sci Transl Med 2022;14:eabm1375. [PMID: 35196021 DOI: 10.1126/scitranslmed.abm1375] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 13.0] [Reference Citation Analysis]
|
| 20 |
Berger M, Barone M, Carnevale-schianca F, De Gobbi M, Nicoli P, Caravelli D, Cilloni D, Paruzzo L, Spadea M, Mareschi K, Aglietta M, Fagioli F. HSCT with Mismatched Unrelated Donors (MMUD): A Comparison of Different Platforms for GvHD Prophylaxis. Transplantology 2022;3:51-67. [DOI: 10.3390/transplantology3010006] [Reference Citation Analysis]
|
| 21 |
Héritier J, Medinger M, Heim D, Baldomero H, Arranto C, Halter JP, Passweg JR, Kleber M. Optimized cyclosporine starting dose may reduce risk of acute GvHD after allogeneic hematopoietic cell transplantation: a single-center cohort study. Bone Marrow Transplant 2022. [PMID: 35132203 DOI: 10.1038/s41409-022-01598-6] [Reference Citation Analysis]
|
| 22 |
Shen M, Zhang X, Xu L, Wang Y, Yan C, Chen H, Chen Y, Han W, Wang F, Wang J, Zhao X, Qin Y, Chang Y, Liu K, Huang X, Mo X. Preemptive Interferon-α Therapy Could Protect Against Relapse and Improve Survival of Acute Myeloid Leukemia Patients After Allogeneic Hematopoietic Stem Cell Transplantation: Long-Term Results of Two Registry Studies. Front Immunol 2022;13:757002. [DOI: 10.3389/fimmu.2022.757002] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 23 |
Jain AG, Elmariah H. BMT for Myelodysplastic Syndrome: When and Where and How. Front Oncol 2021;11:771614. [PMID: 35070975 DOI: 10.3389/fonc.2021.771614] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 24 |
Galli E, Metafuni E, Giammarco S, Limongiello MA, Innocenti I, Autore F, Laurenti L, Sorà F, Chiusolo P, Teofili L, Bacigalupo A, Sica S. Triple post transplant cyclophosphamide (PTCY) based GVHD prophylaxis: HLA matched versus HLA haploidentical transplants. Bone Marrow Transplant. [DOI: 10.1038/s41409-022-01574-0] [Reference Citation Analysis]
|
| 25 |
Gibson CJ, Kim HT, Zhao L, Murdock HM, Hambley B, Ogata A, Madero-Marroquin R, Wang S, Green L, Fleharty M, Dougan T, Cheng CA, Blumenstiel B, Cibulskis C, Tsuji J, Duran M, Gocke CD, Antin JH, Nikiforow S, DeZern AE, Chen YB, Ho VT, Jones RJ, Lennon NJ, Walt DR, Ritz J, Soiffer RJ, Gondek LP, Lindsley RC. Donor Clonal Hematopoiesis and Recipient Outcomes After Transplantation. J Clin Oncol 2022;40:189-201. [PMID: 34793200 DOI: 10.1200/JCO.21.02286] [Cited by in Crossref: 33] [Cited by in F6Publishing: 33] [Article Influence: 33.0] [Reference Citation Analysis]
|
| 26 |
Gibson CJ, Kim HT, Zhao L, Murdock HM, Hambley B, Ogata A, Madero-Marroquin R, Wang S, Green L, Fleharty M, Dougan T, Cheng CA, Blumenstiel B, Cibulskis C, Tsuji J, Duran M, Gocke CD, Antin JH, Nikiforow S, DeZern AE, Chen YB, Ho VT, Jones RJ, Lennon NJ, Walt DR, Ritz J, Soiffer RJ, Gondek LP, Lindsley RC. Donor Clonal Hematopoiesis and Recipient Outcomes After Transplantation. J Clin Oncol 2022;40:189-201. [PMID: 34793200 DOI: 10.1200/JCO.21.02286] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
|
| 27 |
Wolff D. Age Alone Does Not Matter?! Transplantation and Cellular Therapy 2022;28:3-4. [DOI: 10.1016/j.jtct.2021.12.003] [Reference Citation Analysis]
|
| 28 |
Kobayashi S. What are the risks and benefit of a transplant for elderly patients? Japanese Journal of Transplantation and Cellular Therapy 2022;11:22-35. [DOI: 10.7889/tct-21-015] [Reference Citation Analysis]
|
| 29 |
Hegde P, Rybicki L, Serafino S, Ferraro C, Kalaycio M, Sobecks R, Gerds AT, Caroniti S, Corrigan D, Giannetti K, Elberson J, Hodgeman B, Starn J, Dabney J, McLellan L, Majhail NS, Hamilton BK. Day 100 risk assessment tool predicts overall survival in allogeneic hematopoietic cell transplantation. Bone Marrow Transplant 2022;57:131-3. [PMID: 34628474 DOI: 10.1038/s41409-021-01491-8] [Reference Citation Analysis]
|
| 30 |
Sabatelli L, Keränen M, Viayna E, Roset M, Lara N, Thunström D, Pfeiffer M, Nicklasson M, Itälä-Remes M. Burden of hospitalizations and outpatient visits associated with moderate and severe acute graft-versus-host disease in Finland and Sweden: a real-world data study. Support Care Cancer 2022;30:5125-35. [PMID: 35235039 DOI: 10.1007/s00520-022-06915-9] [Reference Citation Analysis]
|
| 31 |
Luo XH, Poiret T, Liu Z, Meng Q, Nagchowdhury A, Ljungman P. Different recovery patterns of CMV-specific and WT1-specific T cells in patients with acute myeloid leukemia undergoing allogeneic hematopoietic cell transplantation: Impact of CMV infection and leukemia relapse. Front Immunol 2022;13:1027593. [PMID: 36824620 DOI: 10.3389/fimmu.2022.1027593] [Reference Citation Analysis]
|
| 32 |
Magenau JM, Peltier D, Riwes M, Pawarode A, Parkin B, Braun T, Anand S, Ghosh M, Maciejewski J, Yanik G, Choi SW, Talpaz M, Reddy P. Type 1 interferon to prevent leukemia relapse after allogeneic transplantation. Blood Adv 2021;5:5047-56. [PMID: 34607341 DOI: 10.1182/bloodadvances.2021004908] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 33 |
Khanolkar RA, Faridi RM, Kinzel M, Jamani K, Savoie ML, Shafey M, Khan FM, Storek J. Impact of FLT3 internal tandem duplication and NPM1 mutations in acute myeloid leukemia treated with allogeneic hematopoietic cell transplantation. Cytotherapy 2021:S1465-3249(21)00852-5. [PMID: 34863627 DOI: 10.1016/j.jcyt.2021.10.006] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
|
| 34 |
Xu LP, Yu Y, Cheng YF, Zhang YY, Mo XD, Han TT, Wang FR, Yan CH, Sun YQ, Chen YH, Wang JZ, Xu ZL, Tang FF, Han W, Wang Y, Zhang XH, Huang XJ. Development and validation of a mortality predicting scoring system for severe aplastic anaemia patients receiving haploidentical allogeneic transplantation. Br J Haematol 2021. [PMID: 34741461 DOI: 10.1111/bjh.17916] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 35 |
Zhang T, Bao X, Qiu H, Tang X, Han Y, Fu C, Sun A, Ruan C, Wu D, Chen S, Xu Y. Development of a Nomogram for Predicting the Cumulative Incidence of Disease Recurrence of AML After Allo-HSCT. Front Oncol 2021;11:732088. [PMID: 34646774 DOI: 10.3389/fonc.2021.732088] [Reference Citation Analysis]
|
| 36 |
Kennedy VE, Olin RL. Haematopoietic stem-cell transplantation in older adults: geriatric assessment, donor considerations, and optimisation of care. Lancet Haematol 2021;8:e853-61. [PMID: 34624239 DOI: 10.1016/S2352-3026(21)00231-3] [Cited by in Crossref: 6] [Cited by in F6Publishing: 1] [Article Influence: 3.0] [Reference Citation Analysis]
|
| 37 |
Gibson CJ, Kim HT, Zhao L, Murdock HM, Hambley B, Ogata A, Madero-marroquin R, Wang S, Green L, Fleharty M, Dougan T, Cheng C, Blumenstiel B, Cibulskis C, Tsuji J, Duran M, Gocke CD, Antin JH, Nikiforow S, Dezern AE, Chen Y, Ho VT, Jones RJ, Lennon NJ, Walt DR, Ritz J, Soiffer RJ, Gondek LP, Lindsley RC. Donor clonal hematopoiesis and recipient outcomes after transplantation.. [DOI: 10.1101/2021.09.25.21263697] [Reference Citation Analysis]
|
| 38 |
Lazzari L, Ruggeri A, Lupo Stanghellini MT, Mastaglio S, Messina C, Giglio F, Lorusso A, Perini T, Piemontese S, Marcatti M, Lorentino F, Xue E, Clerici D, Corti C, Bernardi M, Assanelli A, Greco R, Ciceri F, Peccatori J. Treosulfan-Based Conditioning Regimen Prior to Allogeneic Stem Cell Transplantation: Long-Term Results From a Phase 2 Clinical Trial. Front Oncol 2021;11:731478. [PMID: 34568066 DOI: 10.3389/fonc.2021.731478] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
|
| 39 |
Peña M, Salas MQ, Mussetti A, Moreno-Gonzalez G, Bosch A, Patiño B, Jiménez L, Kara M, Parody R, Sureda A. Pretransplantation EASIX predicts intensive care unit admission in allogeneic hematopoietic cell transplantation. Blood Adv 2021;5:3418-26. [PMID: 34495311 DOI: 10.1182/bloodadvances.2021004812] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 40 |
Friend BD, Schiller GJ. Beyond steroids: A systematic review and proposed solutions to managing acute graft-versus-host disease in adolescents and young adults. Blood Rev 2021;:100886. [PMID: 34509319 DOI: 10.1016/j.blre.2021.100886] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
|
| 41 |
Beauverd Y, Morin S, Stephan C, De Ramon Ortiz C, Fabra Urdiola M, Giannotti F, Mahne E, Mamez AC, Mappoura M, Simonetta F, Tran TA, Ayer C, Noetzlin S, Verdon I, Masouridi-Levrat S, Chalandon Y. The EBMT Cytogenetic Risk Score maintains its prognostic significance in acute myeloid leukemia following allogeneic stem cell transplantation in a cohort with 40% of patients transplanted with in vitro partial T-cell depleted graft. Bone Marrow Transplant 2021;56:2284-6. [PMID: 34007052 DOI: 10.1038/s41409-021-01334-6] [Reference Citation Analysis]
|
| 42 |
Debureaux PE, Bourrier P, Rautou PE, Zagdanski AM, De Boutiny M, Pagliuca S, Sutra Del Galy A, Robin M, Peffault de Latour R, Plessier A, Sicre de Fontbrune F, Xhaard A, de Lima Prata PH, Valla D, Socié G, Michonneau D. Elastography improves accuracy of early hepato-biliary complications diagnosis after allogeneic stem cell transplantation. Haematologica 2021;106:2374-83. [PMID: 32732366 DOI: 10.3324/haematol.2019.245407] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 2.5] [Reference Citation Analysis]
|
| 43 |
Harada K, Kimura SI, Fuji S, Najima Y, Yakushijin K, Uchida N, Onizuka M, Ikegame K, Yano S, Shingai N, Matsuoka KI, Onishi Y, Sawa M, Takada S, Kawakita T, Fukuda T, Kanda J, Atsuta Y, Nakasone H. Prognostic factors in salvage transplantation for graft failure following allogeneic hematopoietic stem cell transplantation. Bone Marrow Transplant 2021;56:2183-93. [PMID: 33927346 DOI: 10.1038/s41409-021-01310-0] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 44 |
Derenzini E, Tabanelli V, Sammassimo S, Mazzara S, Motta G, Melle F, Vanazzi A, Calleri A, Fiori S, Finazzi MC, Barbanti MC, Ramadan S, Gandini S, Pastano R, Rambaldi A, Pileri S, Tarella C. Pre-existing immune checkpoints activation predicts relapse after allogeneic stem cell transplantation in lymphoma. Bone Marrow Transplant 2021;56:2280-3. [PMID: 33963303 DOI: 10.1038/s41409-021-01320-y] [Reference Citation Analysis]
|
| 45 |
Kurosawa S, Yamaguchi T, Mori A, Tsukagoshi M, Okuda I, Kayama M, Fuji S, Yamashita T, Ogawa C, Ito A, Tanaka T, Inamoto Y, Kim SW, Fukuda T. Prognostic Impact of Pretransplantation Quality of Life and Its Post-Transplantation Longitudinal Change after Allogeneic Hematopoietic Cell Transplantation: A Prospective Study That Administered the Short-Form Health Survey (SF-12) and EuroQol 5. Transplant Cell Ther 2021:S2666-6367(21)01108-8. [PMID: 34371214 DOI: 10.1016/j.jtct.2021.07.026] [Reference Citation Analysis]
|
| 46 |
Sheth V, Potter V, de Lavallade H, Gandhi S, Kulasekararaj A, Krishnamurthy P, Mehra V, Dazzi F, Mufti G, Pagliuca A, Mclornan D, Raj K. Mixed T cell lineage chimerism in acute leukemia/MDS using pre-emptive donor lymphocyte infusion strategy-Is it prognostic?-a single-center retrospective study. Blood Cancer J 2021;11:128. [PMID: 34253713 DOI: 10.1038/s41408-021-00519-y] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 47 |
Gjærde LK, Sørensen ALT, Hjorth von Stemann J, Fischer-Nielsen A, Hansen MB, Sengeløv H, Ostrowski SR. Platelet and Red Blood Cell Transfusions and Risk of Acute Graft-versus-Host Disease after Myeloablative Allogeneic Hematopoietic Cell Transplantation. Transplant Cell Ther 2021:S2666-6367(21)01036-8. [PMID: 34252580 DOI: 10.1016/j.jtct.2021.07.001] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
|
| 48 |
Yegin ZA, Özkurt ZN, Dikyar A, Kaynar LA, Karacaoğlu Ö, Yağcı M. Hematopoietic Cell Transplant-Composite Risk (HCT-CR): A Novel Predictor of Prognosis in Acute Leukemia Patients Undergoing Allogeneic Hematopoietic Stem Cell Transplantation. Transplant Proc 2021;53:2013-20. [PMID: 34246474 DOI: 10.1016/j.transproceed.2021.06.017] [Reference Citation Analysis]
|
| 49 |
Qayed M, Ahn KW, Kitko CL, Johnson MH, Shah NN, Dvorak C, Mellgren K, Friend BD, Verneris MR, Leung W, Toporski J, Levine J, Chewning J, Wayne A, Kapoor U, Triplett B, Schultz KR, Yanik GA, Eapen M. A validated pediatric disease risk index for allogeneic hematopoietic cell transplantation. Blood 2021;137:983-93. [PMID: 33206937 DOI: 10.1182/blood.2020009342] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 5.0] [Reference Citation Analysis]
|
| 50 |
Gagelmann N, Kröger N. Dose intensity for conditioning in allogeneic hematopoietic cell transplantation: can we recommend "when and for whom" in 2021? Haematologica 2021;106:1794-804. [PMID: 33730842 DOI: 10.3324/haematol.2020.268839] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 6.0] [Reference Citation Analysis]
|
| 51 |
Modi D, Kondrat K, Kim S, Deol A, Ayash L, Ratanatharathorn V, Uberti JP. Post-transplant Cyclophosphamide Versus Thymoglobulin in HLA-Mismatched Unrelated Donor Transplant for Acute Myelogenous Leukemia and Myelodysplastic Syndrome. Transplant Cell Ther 2021;27:760-7. [PMID: 34174469 DOI: 10.1016/j.jtct.2021.06.018] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 3.0] [Reference Citation Analysis]
|
| 52 |
van der Velden WJFM, Choi G, de Witte MA, van der Meer A, de Haan AFJ, Blijlevens NMA, Huls G, Kuball J, van Dorp S. Anti-thymocyte globulin with CsA and MMF as GVHD prophylaxis in nonmyeloablative HLA-mismatched allogeneic HCT. Bone Marrow Transplant 2021. [PMID: 34148060 DOI: 10.1038/s41409-021-01369-9] [Reference Citation Analysis]
|
| 53 |
Islam P, Tang H, Jin H, Cao F, Bohannon LM, Ren Y, Chao NJ, Choi T, Gasparetto C, Horwitz ME, Long GD, Lopez RD, Rizzieri DA, Sarantopoulos S, Sung AD. Female Sex Is Associated with Improved Long-Term Survival Following Allogeneic Hematopoietic Stem Cell Transplantation. Transplant Cell Ther 2021;27:784.e1-7. [PMID: 34146734 DOI: 10.1016/j.jtct.2021.06.012] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
|
| 54 |
Duléry R, Mohty R, Labopin M, Sestili S, Malard F, Brissot E, Battipaglia G, Médiavilla C, Banet A, Van de Wyngaert Z, Paviglianiti A, Belhocine R, Isnard F, Lapusan S, Adaeva R, Vekhoff A, Ledraa T, Legrand O, Cohen A, Bonnin A, Ederhy S, Mohty M. Early Cardiac Toxicity Associated With Post-Transplant Cyclophosphamide in Allogeneic Stem Cell Transplantation. JACC CardioOncol 2021;3:250-9. [PMID: 34396331 DOI: 10.1016/j.jaccao.2021.02.011] [Cited by in Crossref: 13] [Cited by in F6Publishing: 14] [Article Influence: 6.5] [Reference Citation Analysis]
|
| 55 |
Aladağ E, Demiroğlu H, Büyükaşık Y, Göker H. Comparison of Risk Scoring Systems in HLA-Matched Related Allogeneic Hematopoietic Stem Cell Transplantation: A Retrospective Cohort Study. Turk J Haematol 2021;38:138-44. [PMID: 32539316 DOI: 10.4274/tjh.galenos.2020.2020.0178] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
|
| 56 |
Zuanelli Brambilla C, Lobaugh SM, Ruiz JD, Dahi PB, Goldberg AD, Young JW, Gyurkocza B, Shaffer BC, Ponce DM, Tamari R, Sanchez Escamilla M, Castillo Flores N, Politikos I, Scordo M, Shah GL, Cho C, Lin RJ, Maloy MA, Devlin SM, Jakubowski AA, Berman E, Stein EM, Papadopoulos EB, Perales MA, Tallman MS, Giralt SA, Smith M. Relapse after Allogeneic Stem Cell Transplantation of Acute Myelogenous Leukemia and Myelodysplastic Syndrome and the Importance of Second Cellular Therapy. Transplant Cell Ther 2021;27:771.e1-771.e10. [PMID: 34033977 DOI: 10.1016/j.jtct.2021.05.011] [Reference Citation Analysis]
|
| 57 |
Mariotti J, Raiola AM, Evangelista A, Carella AM, Martino M, Patriarca F, Risitano A, Bramanti S, Busca A, Giaccone L, Brunello L, Merla E, Savino L, Loteta B, Console G, Fanin R, Sperotto A, Marano L, Marotta S, Frieri C, Sica S, Chiusolo P, Harbi S, Furst S, Santoro A, Bacigalupo A, Blaise D, Angelucci E, Mavilio D, Castagna L, Bruno B. Impact of donor age and kinship on clinical outcomes after T-cell-replete haploidentical transplantation with PT-Cy. Blood Adv 2020;4:3900-12. [PMID: 32813875 DOI: 10.1182/bloodadvances.2020001620] [Cited by in Crossref: 20] [Cited by in F6Publishing: 20] [Article Influence: 10.0] [Reference Citation Analysis]
|
| 58 |
Modi D, Chi J, Kim S, Deol A, Ayash L, Ratanatharathorn V, Uberti JP. Outcomes of Fludarabine, Melphalan and Total Body Irradiation as a Reduced Intensity Conditioning Regimen in Matched Donor Allogeneic Peripheral Blood Stem Cell Transplantation. Transplant Cell Ther 2021;27:665.e1-7. [PMID: 33991722 DOI: 10.1016/j.jtct.2021.04.029] [Reference Citation Analysis]
|
| 59 |
Arab Borzu Z, Khadembashi N, Hajifathali A, Baghestani A, Roshandel E. Survival Rate and Prognostic Factors Among Patients Undergoing Hematopoietic Stem Cell Transplantation: Using the Joint Model. Int J Cancer Manag 2021;14. [DOI: 10.5812/ijcm.106846] [Reference Citation Analysis]
|
| 60 |
Bento L, Gutiérrez A, Novelli S, Montoro J, Piñana JL, López-Corral L, Cabrero M, Martín-Sancho A, Gutiérrez-García G, Ortiz-Moscovich M, Bastos-Oreiro M, Dorado N, Pérez A, Hernani R, Ferrà C, Parody R, García-Cadenas I, Herrera P, Rodríguez G, Rodríguez N, Martín C, Yáñez L, Zanabili J, Varela MR, López-Godino O, Heras I, Español I, Martínez C, Pérez-Simón JA, Solano C, Sureda A, Sierra J, Sampol A, Caballero D; Grupo Español de Trasplante Hematopoyético (GETH) and Grupo Español de Linfoma y Trasplante Autólogo (GELTAMO). Allogeneic stem cell transplantation as a curative option in relapse/refractory diffuse large B cell lymphoma: Spanish multicenter GETH/GELTAMO study. Bone Marrow Transplant 2021;56:1919-28. [PMID: 33767400 DOI: 10.1038/s41409-021-01264-3] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
|
| 61 |
Schäfer H, Blümel-Lehmann J, Ihorst G, Bertz H, Wäsch R, Zeiser R, Finke J, Marks R. A prospective single-center study on CNI-free GVHD prophylaxis with everolimus plus mycophenolate mofetil in allogeneic HCT. Ann Hematol 2021;100:2095-103. [PMID: 33755792 DOI: 10.1007/s00277-021-04487-y] [Reference Citation Analysis]
|
| 62 |
Shouval R, Fein JA, Labopin M, Cho C, Bazarbachi A, Baron F, Bug G, Ciceri F, Corbacioglu S, Galimard JE, Giebel S, Gilleece MH, Giralt S, Jakubowski A, Montoto S, O'Reilly RJ, Papadopoulos EB, Peric Z, Ruggeri A, Sanz J, Sauter CS, Savani BN, Schmid C, Spyridonidis A, Tamari R, Versluis J, Yakoub-Agha I, Perales MA, Mohty M, Nagler A. Development and validation of a disease risk stratification system for patients with haematological malignancies: a retrospective cohort study of the European Society for Blood and Marrow Transplantation registry. Lancet Haematol 2021;8:e205-15. [PMID: 33636142 DOI: 10.1016/S2352-3026(20)30394-X] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 4.5] [Reference Citation Analysis]
|
| 63 |
Modi D, Singh V, Kim S, Ayash L, Deol A, Ratanatharathorn V, Uberti JP. Comparison of myeloablative and reduced intensity conditioning unrelated donor allogeneic peripheral blood stem cell transplant outcomes for AML using thymoglobulin for GVHD prophylaxis. Ann Hematol 2021;100:969-78. [PMID: 33594448 DOI: 10.1007/s00277-021-04445-8] [Reference Citation Analysis]
|
| 64 |
Mo X, Zhang X, Xu L, Wang Y, Yan C, Chen H, Chen Y, Han W, Wang F, Wang J, Liu K, Huang X. Disease Risk Comorbidity Index for Patients Receiving Haploidentical Allogeneic Hematopoietic Transplantation. Engineering 2021;7:162-169. [DOI: 10.1016/j.eng.2020.12.005] [Cited by in Crossref: 6] [Article Influence: 3.0] [Reference Citation Analysis]
|
| 65 |
Pahl A, Waibel S, Wehrle A, Ihorst G, Gollhofer A, Bertz H. Cardiopulmonary performance in allogeneic hematopoietic cell transplantation recipients-evaluation of pre-transplant risk assessments. Bone Marrow Transplant 2021;56:1325-34. [PMID: 33408382 DOI: 10.1038/s41409-020-01191-9] [Reference Citation Analysis]
|
| 66 |
Kennedy VE, Muffly LS. Pretransplant Assessment for Hematopoietic Cell Transplantation Recipients and Donors. Blood and Marrow Transplant Handbook 2021. [DOI: 10.1007/978-3-030-53626-8_4] [Reference Citation Analysis]
|
| 67 |
Mishra A, Bigam KD, Extermann M, Faramand R, Thomas K, Pidala JA, Baracos VE. Sarcopenia and low muscle radiodensity associate with impaired FEV(1) in allogeneic haematopoietic stem cell transplant recipients. J Cachexia Sarcopenia Muscle 2020;11:1570-9. [PMID: 32729255 DOI: 10.1002/jcsm.12604] [Cited by in Crossref: 17] [Cited by in F6Publishing: 14] [Article Influence: 5.7] [Reference Citation Analysis]
|
| 68 |
Morrissey H, Ball P, Mandal A, Nevil A, Paneesha S, Basu S, Karim F, Hossain MI, Phillips N, Khawaja J, Stone J, Murray D, Randall K, Murthy V, Kishore B, Nikolousis M, Pratt G, Neilson J, Pemberton N, Wandroo F. COVID-19 in haematology patients: a multicentre West Midlands clinical outcomes analysis on behalf of the West Midlands Research Consortium. Br J Haematol 2021;192:e11-4. [PMID: 33151540 DOI: 10.1111/bjh.17136] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
|
| 69 |
Sato T, Kawashima N, Ito M, Atsuta Y, Kagaya Y, Seto A, Morishita T, Fukushima N, Ozawa Y, Miyamura K. Day 0 bone marrow pathology of allogeneic hematopoietic stem cell transplantation is a novel prognostic factor in myeloid malignancies. Blood Cell Ther 2020;3:84-91. [PMID: 36711006 DOI: 10.31547/bct-2020-007] [Reference Citation Analysis]
|
| 70 |
Beauverd Y, Morin S, Nabergoj M, Stephan C, De Ramon Ortiz C, Mamez AC, Mahne E, Petropoulou A, Giannotti F, Ayer C, Bruno B, Bounaix L, Anastasiou M, Mappoura M, Tran TA, Masouridi-Levrat S, Chalandon Y. Evaluation of Disease Risk Comorbidity Index after Allogeneic Stem Cell Transplantation in a Cohort with Patients Undergoing Transplantation with In Vitro Partially T Cell Depleted Grafts. Transplant Cell Ther 2021;27:67.e1-7. [PMID: 32980547 DOI: 10.1016/j.bbmt.2020.09.022] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
|
| 71 |
Gambacorta V, Parolini R, Xue E, Greco R, Bouwmans EE, Toffalori C, Giglio F, Assanelli A, Stanghellini MTL, Ambrosi A, Mazzi B, Mulder W, Corti C, Peccatori J, Ciceri F, Vago L. Quantitative PCR-based chimerism in bone marrow or peripheral blood to predict acute myeloid leukemia relapse in high-risk patients: results from the KIM-PB prospective study. Haematologica 2020;106:1480-3. [PMID: 33054102 DOI: 10.3324/haematol.2019.238543] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
|
| 72 |
Modi D, Kim S, Surapaneni M, Ayash L, Ratanatharathorn V, Uberti JP, Deol A. Absolute lymphocyte count on the first day of thymoglobulin predicts relapse-free survival in matched unrelated peripheral blood stem cell transplantation. Leukemia & Lymphoma 2020;61:3137-45. [DOI: 10.1080/10428194.2020.1805114] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 2.3] [Reference Citation Analysis]
|
| 73 |
Maung KK, Chen BJ, Barak I, Li Z, Rizzieri DA, Gasparetto C, Sullivan KM, Long GD, Engemann AM, Waters-Pick B, Nichols KR, Lopez R, Kang Y, Sarantopoulos S, Sung AD, Chao NJ, Horwitz ME. Phase I dose escalation study of naive T-cell depleted donor lymphocyte infusion following allogeneic stem cell transplantation. Bone Marrow Transplant 2021;56:137-43. [PMID: 32624583 DOI: 10.1038/s41409-020-0991-5] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 1.7] [Reference Citation Analysis]
|
| 74 |
Pagliuca S, Prata PH, Xhaard A, Frieri C, Giannoni L, Sutra Del Galy A, Brignier A, Sicre de Fontbrune F, Michonneau D, Dhedin N, Peffault de Latour R, Socié G, Robin M. Long-term outcomes and risk factor analysis of steroid-refractory graft versus host disease after hematopoietic stem cell transplantation. Bone Marrow Transplant 2021;56:38-49. [PMID: 32587336 DOI: 10.1038/s41409-020-0977-3] [Cited by in Crossref: 4] [Cited by in F6Publishing: 6] [Article Influence: 1.3] [Reference Citation Analysis]
|
| 75 |
Shouval R, Fein JA, Shouval A, Danylesko I, Shem-Tov N, Zlotnik M, Yerushalmi R, Shimoni A, Nagler A. External validation and comparison of multiple prognostic scores in allogeneic hematopoietic stem cell transplantation. Blood Adv 2019;3:1881-90. [PMID: 31221661 DOI: 10.1182/bloodadvances.2019032268] [Cited by in Crossref: 44] [Cited by in F6Publishing: 45] [Article Influence: 14.7] [Reference Citation Analysis]
|
| 76 |
Koldej RM, Perera T, Collins J, Ritchie DS. Association between P2X7 Polymorphisms and Post-Transplant Outcomes in Allogeneic Haematopoietic Stem Cell Transplantation. Int J Mol Sci 2020;21:E3772. [PMID: 32471261 DOI: 10.3390/ijms21113772] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.7] [Reference Citation Analysis]
|
| 77 |
Kurosawa S, Shimomura Y, Tachibana T, Ishiyama K, Ota S, Kobayashi T, Uchida N, Fukushima K, Ashida T, Matsuoka KI, Kanda J, Ichinohe T, Atsuta Y, Murata M, Aoki J. Outcome of Allogeneic Hematopoietic Stem Cell Transplantation in Patients with Myelodysplastic/Myeloproliferative Neoplasms-Unclassifiable: A Retrospective Nationwide Study of the Japan Society for Hematopoietic Cell Transplantation. Biol Blood Marrow Transplant 2020;26:1607-11. [PMID: 32454216 DOI: 10.1016/j.bbmt.2020.05.013] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
|
| 78 |
Im A, Rashidi A, Wang T, Hemmer M, MacMillan ML, Pidala J, Jagasia M, Pavletic S, Majhail NS, Weisdorf D, Abdel-Azim H, Agrawal V, Al-Homsi AS, Aljurf M, Askar M, Auletta JJ, Bashey A, Beitinjaneh A, Bhatt VR, Byrne M, Cahn JY, Cairo M, Castillo P, Cerny J, Chhabra S, Choe H, Ciurea S, Daly A, Perez MAD, Farhadfar N, Gadalla SM, Gale R, Ganguly S, Gergis U, Hanna R, Hematti P, Herzig R, Hildebrandt GC, Lad DP, Lee C, Lehmann L, Lekakis L, Kamble RT, Kharfan-Dabaja MA, Khandelwal P, Martino R, Murthy HS, Nishihori T, O'Brien TA, Olsson RF, Patel SS, Perales MA, Prestidge T, Qayed M, Romee R, Schoemans H, Seo S, Sharma A, Solh M, Strair R, Teshima T, Urbano-Ispizua A, Van der Poel M, Vij R, Wagner JL, William B, Wirk B, Yared JA, Spellman SR, Arora M, Hamilton BK. Risk Factors for Graft-versus-Host Disease in Haploidentical Hematopoietic Cell Transplantation Using Post-Transplant Cyclophosphamide. Biol Blood Marrow Transplant 2020;26:1459-68. [PMID: 32434056 DOI: 10.1016/j.bbmt.2020.05.001] [Cited by in Crossref: 21] [Cited by in F6Publishing: 22] [Article Influence: 7.0] [Reference Citation Analysis]
|
| 79 |
Sterling C, Webster J. Harnessing the immune system after allogeneic stem cell transplant in acute myeloid leukemia. Am J Hematol 2020;95:529-47. [PMID: 32022292 DOI: 10.1002/ajh.25750] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 3.7] [Reference Citation Analysis]
|
| 80 |
Penack O, Peczynski C, van der Werf S, Finke J, Ganser A, Schoemans H, Pavlu J, Niittyvuopio R, Schroyens W, Kaynar L, Blau IW, van der Velden WJFM, Sierra J, Cortelezzi A, Wulf G, Turlure P, Rovira M, Ozkurt Z, Pascual-Cascon MJ, Moreira MC, Clausen J, Greinix H, Duarte RF, Basak GW. Association of Serum Ferritin Levels Before Start of Conditioning With Mortality After alloSCT - A Prospective, Non-interventional Study of the EBMT Transplant Complications Working Party. Front Immunol 2020;11:586. [PMID: 32351502 DOI: 10.3389/fimmu.2020.00586] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 1.7] [Reference Citation Analysis]
|
| 81 |
Bejanyan N, Brunstein CG, Cao Q, Lazaryan A, Ustun C, Warlick ED, Arora M, Wagner JE, Weisdorf DJ. Predictive value of disease risk comorbidity index for overall survival after allogeneic hematopoietic transplantation. Blood Adv 2019;3:230-6. [PMID: 30674457 DOI: 10.1182/bloodadvances.2018018549] [Cited by in Crossref: 12] [Cited by in F6Publishing: 13] [Article Influence: 4.0] [Reference Citation Analysis]
|
| 82 |
DiMaggio E, Zhou JM, Caddell R, Tombleson R, Perkins J, Anasetti C, Khimani F, Pidala J, Nishihori T, Perez L, Betts B, Fernandez HF, Mishra A. Reduced-intensity fludarabine/melphalan confers similar survival to busulfan/fludarabine myeloablative regimens for patients with acute myeloid leukemia and myelodysplasia. Leuk Lymphoma 2020;61:1678-87. [PMID: 32133897 DOI: 10.1080/10428194.2020.1731498] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 83 |
Harada K, Fuji S, Seo S, Kanda J, Ueki T, Kimura F, Kato K, Uchida N, Ikegame K, Onizuka M, Matsuoka KI, Doki N, Kawakita T, Onishi Y, Yano S, Fukuda T, Takanashi M, Kanda Y, Atsuta Y, Ogata M; transplant complications working group of the Japan Society for Hematopoietic Cell Transplantation. Comparison of the outcomes after haploidentical and cord blood salvage transplantations for graft failure following allogeneic hematopoietic stem cell transplantation. Bone Marrow Transplant 2020;55:1784-95. [PMID: 32051535 DOI: 10.1038/s41409-020-0821-9] [Cited by in Crossref: 11] [Cited by in F6Publishing: 14] [Article Influence: 3.7] [Reference Citation Analysis]
|
| 84 |
Salas MQ, Prem S, Atenafu EG, Datt Law A, Lam W, Al-shaibani Z, Loach D, Kim D(H, Michelis FV, Lipton JH, Kumar R, Mattsson J, Viswabandya A. Dual T-cell depletion with ATG and PTCy for peripheral blood reduced intensity conditioning allo-HSCT results in very low rates of GVHD. Bone Marrow Transplant 2020;55:1773-83. [DOI: 10.1038/s41409-020-0813-9] [Cited by in Crossref: 24] [Cited by in F6Publishing: 26] [Article Influence: 8.0] [Reference Citation Analysis]
|
| 85 |
Spyridonidis A, Labopin M, Savani BN, Niittyvuopio R, Blaise D, Craddock C, Socié G, Platzbecker U, Beelen D, Milpied N, Cornelissen JJ, Ganser A, Huynh A, Griskevicius L, Giebel S, Aljurf M, Brissot E, Malard F, Esteve J, Peric Z, Baron F, Ruggeri A, Schmid C, Gilleece M, Gorin N, Lanza F, Shouval R, Versluis J, Bug G, Fløisand Y, Ciceri F, Sanz J, Bazarbachi A, Nagler A, Mohty M. Redefining and measuring transplant conditioning intensity in current era: a study in acute myeloid leukemia patients. Bone Marrow Transplant 2020;55:1114-25. [DOI: 10.1038/s41409-020-0803-y] [Cited by in Crossref: 46] [Cited by in F6Publishing: 48] [Article Influence: 15.3] [Reference Citation Analysis]
|
| 86 |
Kongtim P, Hasan O, Perez JMR, Varma A, Wang SA, Patel KP, Chen J, Rondon G, Srour S, Bashir Q, Qazilbash M, Mehta R, Shpall EJ, Alousi A, Khouri I, Kebriaei P, Popat U, Champlin RR, Ciurea SO. Novel Disease Risk Model for Patients with Acute Myeloid Leukemia Receiving Allogeneic Hematopoietic Cell Transplantation. Biology of Blood and Marrow Transplantation 2020;26:197-203. [DOI: 10.1016/j.bbmt.2019.09.006] [Cited by in Crossref: 9] [Cited by in F6Publishing: 12] [Article Influence: 3.0] [Reference Citation Analysis]
|
| 87 |
Harada N, Nakane T, Nakamae M, Hashimoto Y, Okamura H, Nanno S, Nishimoto M, Hirose A, Nakashima Y, Koh H, Hino M, Nakamae H. Pretransplant serum beta-2 microglobulin level is a potential novel prognostic marker of overall survival after allogeneic hematopoietic cell transplantation - a retrospective observational study. Transpl Int 2020;33:391-401. [PMID: 31834655 DOI: 10.1111/tri.13564] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
|
| 88 |
Friend BD, Tang K, Markovic D, Elashoff D, Moore TB, Schiller GJ. Identifying risk factors associated with worse outcomes in adolescents and young adults undergoing hematopoietic stem cell transplantation. Pediatr Blood Cancer 2019;66:e27940. [PMID: 31429528 DOI: 10.1002/pbc.27940] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 3.0] [Reference Citation Analysis]
|
| 89 |
Fujiwara S, Hattori N, Matsui T, Nakata A, Sasaki Y, Shimada S, Murai S, Abe M, Baba Y, Watanuki M, Kawaguchi Y, Arai N, Kabasawa N, Tsukamoto H, Uto Y, Yanagisawa K, Harada H, Nakamaki T. Refined Disease Risk Index for Hematological Malignancies, Including Rare Disorders, After Allogeneic Stem Cell Transplantation. Transplant Proc 2019;51:3437-43. [PMID: 31733801 DOI: 10.1016/j.transproceed.2019.08.044] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
|
| 90 |
Sakatoku K, Ito A, Tajima K, Yamaguchi K, Kuno M, Aoki N, Tanaka T, Kurosawa S, Inamoto Y, Kim SW, Fukuda T. Prognostic significance of low pre-transplant skeletal muscle mass on survival outcomes in patients undergoing hematopoietic stem cell transplantation. Int J Hematol 2020;111:267-77. [PMID: 31713713 DOI: 10.1007/s12185-019-02773-0] [Cited by in Crossref: 8] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 91 |
Luft T, Benner A, Terzer T, Jodele S, Dandoy CE, Storb R, Kordelas L, Beelen D, Gooley T, Sandmaier BM, Sorror M, Zeisbrich M, Radujkovic A, Dreger P, Penack O. EASIX and mortality after allogeneic stem cell transplantation. Bone Marrow Transplant 2020;55:553-61. [PMID: 31558788 DOI: 10.1038/s41409-019-0703-1] [Cited by in Crossref: 31] [Cited by in F6Publishing: 31] [Article Influence: 7.8] [Reference Citation Analysis]
|
| 92 |
Amberge S, Kramer M, Schröttner P, Heidrich K, Schmelz R, Middeke JM, Gunzer F, Hampe J, Schetelig J, Bornhäuser M, Stölzel F. Clostridium Difficile infections in patients with AML or MDS undergoing allogeneic hematopoietic stem cell transplantation identify high risk for adverse outcome. Bone Marrow Transplant 2020;55:367-75. [PMID: 31534193 DOI: 10.1038/s41409-019-0678-y] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 1.5] [Reference Citation Analysis]
|
| 93 |
Wang Y, Wu DP, Liu QF, Xu LP, Liu KY, Zhang XH, Yu WJ, Xu Y, Huang F, Huang XJ. Low-dose post-transplant cyclophosphamide and anti-thymocyte globulin as an effective strategy for GVHD prevention in haploidentical patients. J Hematol Oncol 2019;12:88. [PMID: 31481121 DOI: 10.1186/s13045-019-0781-y] [Cited by in Crossref: 45] [Cited by in F6Publishing: 36] [Article Influence: 11.3] [Reference Citation Analysis]
|
| 94 |
Arcuri LJ, Aguiar MTM, Ribeiro AAF, Pacheco AGF. Haploidentical Transplantation with Post-Transplant Cyclophosphamide versus Unrelated Donor Hematopoietic Stem Cell Transplantation: A Systematic Review and Meta-Analysis. Biol Blood Marrow Transplant 2019;25:2422-30. [PMID: 31386903 DOI: 10.1016/j.bbmt.2019.07.028] [Cited by in Crossref: 25] [Cited by in F6Publishing: 26] [Article Influence: 6.3] [Reference Citation Analysis]
|
| 95 |
Sheth V, Kennedy V, de Lavallade H, Mclornan D, Potter V, Engelhardt BG, Savani B, Chinratanalab W, Goodman S, Greer J, Kassim A, York S, Kenyon M, Gandhi S, Kulasekararaj A, Marsh J, Mufti G, Pagliuca A, Jagasia M, Raj K. Differential Interaction of Peripheral Blood Lymphocyte Counts (ALC) With Different in vivo Depletion Strategies in Predicting Outcomes of Allogeneic Transplant: An International 2 Center Experience. Front Oncol 2019;9:623. [PMID: 31355140 DOI: 10.3389/fonc.2019.00623] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
|
| 96 |
Hamilton BK, Liu Y, Hemmer MT, Majhail N, Ringden O, Kim D, Costa L, Stuart R, Alousi A, Pidala JA, Couriel DR, Aljurf M, Antin JH, Bredeson C, Cahn JY, Cairo M, Choi SW, Dandoy C, Gale RP, Gergis U, Hematti P, Inamoto Y, Kamble RT, MacMillan M, Marks DI, Nemecek E, Nishihori T, Saad A, Savani BN, Schriber J, Seo S, Socié G, Teshima T, Verdonck LF, Waller EK, Wirk M, Spellman SR, Arora M, Chhabra S. Inferior Outcomes with Cyclosporine and Mycophenolate Mofetil after Myeloablative Allogeneic Hematopoietic Cell Transplantation. Biol Blood Marrow Transplant 2019;25:1744-55. [PMID: 31158502 DOI: 10.1016/j.bbmt.2019.05.019] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.5] [Reference Citation Analysis]
|
| 97 |
Tachibana T, Kanda J, Ishizaki T, Najima Y, Tanaka M, Doki N, Fujiwara SI, Kimura SI, Onizuka M, Takahashi S, Saito T, Mori T, Fujisawa S, Sakaida E, Matsumoto K, Aotsuka N, Goto M, Watanabe R, Shono K, Usuki K, Tsukada N, Kanamori H, Kanda Y, Okamoto S; Kanto Study., Group for Cell Therapy (KSGCT). Prognostic index for patients with relapsed or refractory acute myeloid leukemia who underwent hematopoietic cell transplantation: a KSGCT multicenter analysis. Leukemia 2019;33:2610-8. [PMID: 31147621 DOI: 10.1038/s41375-019-0494-9] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 1.8] [Reference Citation Analysis]
|
| 98 |
Jaiswal SR, Bhakuni P, Joy A, Kaushal S, Chakrabarti A, Chakrabarti S. CTLA4Ig Primed Donor Lymphocyte Infusion: A Novel Approach to Immunotherapy after Haploidentical Transplantation for Advanced Leukemia. Biology of Blood and Marrow Transplantation 2019;25:673-82. [DOI: 10.1016/j.bbmt.2018.12.836] [Cited by in Crossref: 19] [Cited by in F6Publishing: 18] [Article Influence: 4.8] [Reference Citation Analysis]
|
| 99 |
Fløisand Y, Lazarevic VL, Maertens J, Mattsson J, Shah NN, Zachée P, Taylor A, Akbari M, Quadri S, Parfionovas A, Chen Y. Safety and Effectiveness of Vedolizumab in Patients with Steroid-Refractory Gastrointestinal Acute Graft-versus-Host Disease: A Retrospective Record Review. Biology of Blood and Marrow Transplantation 2019;25:720-7. [DOI: 10.1016/j.bbmt.2018.11.013] [Cited by in Crossref: 39] [Cited by in F6Publishing: 41] [Article Influence: 9.8] [Reference Citation Analysis]
|
| 100 |
Schneidawind C, Jahnke S, Schober-Melms I, Schumm M, Handgretinger R, Faul C, Kanz L, Bethge W, Schneidawind D. G-CSF administration prior to donor lymphocyte apheresis promotes anti-leukaemic effects in allogeneic HCT patients. Br J Haematol 2019;186:60-71. [PMID: 30916396 DOI: 10.1111/bjh.15881] [Cited by in Crossref: 10] [Cited by in F6Publishing: 12] [Article Influence: 2.5] [Reference Citation Analysis]
|
| 101 |
de Kort EA, de Lil HS, Bremmers MEJ, van Groningen LFJ, Blijlevens NMA, Huls G, Brüggemann RJM, van Dorp S, van der Velden WJFM. Cyclosporine A trough concentrations are associated with acute GvHD after non-myeloablative allogeneic hematopoietic cell transplantation. PLoS One 2019;14:e0213913. [PMID: 30897127 DOI: 10.1371/journal.pone.0213913] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 3.0] [Reference Citation Analysis]
|
| 102 |
Wang K, Lv M, Chang YJ, Zhao XY, Zhao XS, Zhang YY, Sun YQ, Wang ZD, Suo P, Zhou Y, Liu D, Zhai SZ, Hong Y, Wang Y, Zhang XH, Xu LP, Liu KY, Huang XJ. Early myeloid-derived suppressor cells (HLA-DR-/lowCD33+CD16-) expanded by granulocyte colony-stimulating factor prevent acute graft-versus-host disease (GVHD) in humanized mouse and might contribute to lower GVHD in patients post allo-HSCT. J Hematol Oncol 2019;12:31. [PMID: 30885244 DOI: 10.1186/s13045-019-0710-0] [Cited by in Crossref: 25] [Cited by in F6Publishing: 25] [Article Influence: 6.3] [Reference Citation Analysis]
|
| 103 |
Duléry R, Bastos J, Paviglianiti A, Malard F, Brissot E, Battipaglia G, Médiavilla C, Giannotti F, Banet A, de Wyngaert ZV, Ledraa T, Belhocine R, Sestili S, Adaeva R, Lapusan S, Isnard F, Legrand O, Vekhoff A, Rubio MT, Ruggeri A, Mohty M. Thiotepa, Busulfan, and Fludarabine Conditioning Regimen in T Cell-Replete HLA-Haploidentical Hematopoietic Stem Cell Transplantation. Biol Blood Marrow Transplant 2019;25:1407-15. [PMID: 30871978 DOI: 10.1016/j.bbmt.2019.02.025] [Cited by in Crossref: 19] [Cited by in F6Publishing: 19] [Article Influence: 4.8] [Reference Citation Analysis]
|
| 104 |
Poudel SK, de Lima M, Metheny L. Posttransplant maintenance therapy for acute leukemias: . Current Opinion in Hematology 2019;26:96-111. [DOI: 10.1097/moh.0000000000000484] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
|
| 105 |
Ma R, Huang XJ, Xu LP, Liu KY, Zhang XH, Yan CH, Han W, Wang FR, Chen YH, Chen H, Chen Y, Wang JZ, Wang Y. Comparable Outcomes after Hematopoietic Stem Cell Transplantation from Mother Donors and Matched Unrelated Donors in Patients with Hematopoietic Malignancies. Biol Blood Marrow Transplant 2019;25:1210-7. [PMID: 30708190 DOI: 10.1016/j.bbmt.2019.01.030] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
|
| 106 |
Kennedy VE, Muffly LS. Assessment of older adult candidates for allogeneic hematopoietic cell transplantation: updates and remaining questions. Expert Review of Hematology 2019;12:99-106. [DOI: 10.1080/17474086.2019.1568236] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 107 |
Jain T, Kunze KL, Khetarpal BK, McCallen MR, Betcher JA, Ofori HT, Khera N, Slack JL, Leis JF, Sproat LZ, Noel P, Palmer J. Early fluctuations in busulfan levels with therapeutic dose monitoring during allogeneic stem cell transplantation: do they matter? Leuk Lymphoma 2019;60:2034-41. [PMID: 30626239 DOI: 10.1080/10428194.2018.1562183] [Reference Citation Analysis]
|
| 108 |
Yakoub-agha I. Allogeneic Hematopoietic Cell Transplantation in Patients With Myelodysplastic Syndrome. Hematopoietic Cell Transplantation for Malignant Conditions 2019. [DOI: 10.1016/b978-0-323-56802-9.00013-4] [Reference Citation Analysis]
|
| 109 |
Carreras E, Rambaldi A. Evaluation and Counseling of Candidates. The EBMT Handbook 2019. [DOI: 10.1007/978-3-030-02278-5_11] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 110 |
Kawano N, Yoshida S, Shimonodan H, Kuriyama T, Ono N, Himeji D, Tochigi T, Nakaike T, Shimokawa T, Urata S, Yamashita K, Ito M, Koketsu H, Toyofuku A, Muranaka T, Marutsuka K, Mashiba K, Kikuchi I, Makino S, Ochiai H, Shimoda K, Nagafuji K, Mori Y, Miyamoto T, Akashi K. Clinical Features and Treatment Outcomes of Hematopoietic Stem Cell Transplantation During 2006-2016 at a Single Institution in Miyazaki Prefecture. Journal of Hematopoietic Cell Transplantation 2019;8:122-134. [DOI: 10.7889/hct-18-022] [Reference Citation Analysis]
|
| 111 |
McCurdy SR, Kanakry CG, Tsai HL, Gojo I, Smith BD, Gladstone DE, Bolaños-Meade J, Borrello I, Matsui WH, Swinnen LJ, Huff CA, Brodsky RA, Ambinder RF, Fuchs EJ, Rosner GL, Jones RJ, Luznik L. Development of Grade II Acute Graft-versus-Host Disease Is Associated with Improved Survival after Myeloablative HLA-Matched Bone Marrow Transplantation using Single-Agent Post-Transplant Cyclophosphamide. Biol Blood Marrow Transplant 2019;25:1128-35. [PMID: 30599208 DOI: 10.1016/j.bbmt.2018.12.767] [Cited by in Crossref: 28] [Cited by in F6Publishing: 30] [Article Influence: 5.6] [Reference Citation Analysis]
|
| 112 |
Guru Murthy GS, Hari PN, Szabo A, Pasquini M, Narra R, Khan M, Abedin S, Chhabra S, Dhakal B, D'Souza A, Drobyski WR, Rizzo JD, Runaas L, Shah NN, Shaw B, Saber W, Fenske T, Hamadani M. Outcomes of Reduced-Intensity Conditioning Allogeneic Hematopoietic Cell Transplantation Performed in the Inpatient versus Outpatient Setting. Biol Blood Marrow Transplant 2019;25:827-33. [PMID: 30572109 DOI: 10.1016/j.bbmt.2018.12.069] [Cited by in Crossref: 14] [Cited by in F6Publishing: 15] [Article Influence: 2.8] [Reference Citation Analysis]
|
| 113 |
Bondanza A, Ruggeri L, Noviello M, Eikema DJ, Bonini C, Chabannon C, van der Werf S, van Biezen A, de Wreede LC, Crucitti L, Vago L, Merluzzi M, Massei MS, Veelken H, Koc Y, Bader P, Gruhn B, Locatelli F, Ciceri F, Toubert A, Velardi A; EBMT Cell Therapy and Immunobiology Working Party. Beneficial role of CD8+ T-cell reconstitution after HLA-haploidentical stem cell transplantation for high-risk acute leukaemias: results from a clinico-biological EBMT registry study mostly in the T-cell-depleted setting. Bone Marrow Transplant 2019;54:867-76. [PMID: 30531916 DOI: 10.1038/s41409-018-0351-x] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 1.2] [Reference Citation Analysis]
|
| 114 |
Horwitz ME, Wease S, Blackwell B, Valcarcel D, Frassoni F, Boelens JJ, Nierkens S, Jagasia M, Wagner JE, Kuball J, Koh LP, Majhail NS, Stiff PJ, Hanna R, Hwang WYK, Kurtzberg J, Cilloni D, Freedman LS, Montesinos P, Sanz G. Phase I/II Study of Stem-Cell Transplantation Using a Single Cord Blood Unit Expanded Ex Vivo With Nicotinamide. J Clin Oncol 2019;37:367-74. [PMID: 30523748 DOI: 10.1200/JCO.18.00053] [Cited by in Crossref: 66] [Cited by in F6Publishing: 71] [Article Influence: 13.2] [Reference Citation Analysis]
|
| 115 |
Postalcioglu M, Kim HT, Obut F, Yilmam OA, Yang J, Byun BC, Kupiec-weglinski S, Soiffer R, Ritz J, Antin JH, Alyea E, Koreth J, Cutler C, Armand P, Paik JM, Leaf DE, Ho VT, Abdi R. Impact of Thrombotic Microangiopathy on Renal Outcomes and Survival after Hematopoietic Stem Cell Transplantation. Biology of Blood and Marrow Transplantation 2018;24:2344-53. [DOI: 10.1016/j.bbmt.2018.05.010] [Cited by in Crossref: 22] [Cited by in F6Publishing: 23] [Article Influence: 4.4] [Reference Citation Analysis]
|
| 116 |
Harashima S, Yoneda R, Horie T, Fujioka Y, Nakamura F, Kurokawa M, Yoshiuchi K. Psychosocial Assessment of Candidates for Transplantation scale (PACT) and survival after allogeneic hematopoietic stem cell transplantation. Bone Marrow Transplant 2019;54:1013-21. [PMID: 30353064 DOI: 10.1038/s41409-018-0371-6] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 2.2] [Reference Citation Analysis]
|
| 117 |
Sheth V, Nachmias B, Grisariu S, Avni B, Or R, Shapira M. Augmented myeloablative conditioning with thiotepa in acute myeloid leukemia - improved outcomes with similar toxicity. Leuk Lymphoma 2019;60:726-33. [PMID: 30277100 DOI: 10.1080/10428194.2018.1510495] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
|
| 118 |
Kongtim P, Parmar S, Milton DR, Perez JMR, Rondon G, Chen J, Chilkulwar AR, Al-Atrash G, Alousi A, Andersson BS, Im JS, Hosing CM, Bashir Q, Khouri I, Kebriaei P, Oran B, Popat U, Champlin R, Ciurea SO. Impact of a novel prognostic model, hematopoietic cell transplant-composite risk (HCT-CR), on allogeneic transplant outcomes in patients with acute myeloid leukemia and myelodysplastic syndrome. Bone Marrow Transplant 2019;54:839-48. [PMID: 30258129 DOI: 10.1038/s41409-018-0344-9] [Cited by in Crossref: 20] [Cited by in F6Publishing: 21] [Article Influence: 4.0] [Reference Citation Analysis]
|
| 119 |
Ranti J, Kurki S, Salmenniemi U, Putkonen M, Salomäki S, Itälä-Remes M. Early CD8+-recovery independently predicts low probability of disease relapse but also associates with severe GVHD after allogeneic HSCT. PLoS One 2018;13:e0204136. [PMID: 30235281 DOI: 10.1371/journal.pone.0204136] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 120 |
Solh MM, Solomon SR, Morris LE, Zhang X, Holland HK, Bashey A. The Dilemma of Conditioning Intensity: When Does Myeloablative Conditioning Improve Outcomes for Allogeneic Hematopoietic Cell Transplantation. Biol Blood Marrow Transplant 2019;25:606-12. [PMID: 30244109 DOI: 10.1016/j.bbmt.2018.09.012] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 1.6] [Reference Citation Analysis]
|
| 121 |
Gayoso J, Balsalobre P, Kwon M, Herrera P, Bermúdez A, Sampol A, Jiménez S, López-corral L, Serrano D, Piñana JL, Pascual MJ, Heras I, Bento L, Varela R, Humala K, Zabalza A, Laiglesia A, Bastos-oreiro M, Pérez-corral A, Martínez-laperche C, Buño I, Díez-martín JL; GETH (Grupo Español de Trasplante Hematopoyético), Spain. Busulfan-based myeloablative conditioning regimens for haploidentical transplantation in high-risk acute leukemias and myelodysplastic syndromes. Eur J Haematol 2018;101:332-9. [DOI: 10.1111/ejh.13103] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 1.6] [Reference Citation Analysis]
|
| 122 |
Schneidawind C, Hagmaier V, Faul C, Kanz L, Bethge W, Schneidawind D. Second allogeneic hematopoietic cell transplantation enables long-term disease-free survival in relapsed acute leukemia. Ann Hematol 2018;97:2491-500. [PMID: 30066039 DOI: 10.1007/s00277-018-3454-y] [Cited by in Crossref: 20] [Cited by in F6Publishing: 20] [Article Influence: 4.0] [Reference Citation Analysis]
|
| 123 |
Ben Othman T, Ghedira H, Ben Abdejlil N, Lakhal A, Torjemane L, Ben Hamed L, Hamida S, Zouari B, Ladeb S. Filgrastim following HLA-Identical Allogeneic Bone Marrow Transplantation: Long-Term Outcomes of a Randomized Trial. Biol Blood Marrow Transplant 2018;24:2459-65. [PMID: 30036571 DOI: 10.1016/j.bbmt.2018.07.024] [Reference Citation Analysis]
|
| 124 |
Hagen PA, Adams W, Smith S, Tsai S, Stiff P. Low mean post-transplantation tacrolimus levels in weeks 2–3 correlate with acute graft-versus-host disease in allogeneic hematopoietic stem cell transplantation from related and unrelated donors. Bone Marrow Transplant 2019;54:155-8. [DOI: 10.1038/s41409-018-0267-5] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 1.6] [Reference Citation Analysis]
|
| 125 |
Lin XJ, Dai HP, Wang AJ, Chen F, Ma X, Sun AN, Zhu XM, Qiu HY, Jin ZM, Miao M, Xue SL, Mao XL, Wu DP, Tang XW. Effects of preemptive interferon-α monotherapy in acute leukemia patients with relapse tendency after allogeneic hematopoietic stem cell transplantation: a case-control study. Ann Hematol 2018;97:2195-204. [PMID: 29995264 DOI: 10.1007/s00277-018-3429-z] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 1.8] [Reference Citation Analysis]
|
| 126 |
Yang B, Yu R, Cai L, Bin Guo, Chen H, Zhang H, He P, Lu X. Haploidentical versus matched donor stem cell transplantation for patients with hematological malignancies: a systemic review and meta-analysis. Bone Marrow Transplant 2019;54:99-122. [PMID: 29988061 DOI: 10.1038/s41409-018-0239-9] [Cited by in Crossref: 15] [Cited by in F6Publishing: 17] [Article Influence: 3.0] [Reference Citation Analysis]
|
| 127 |
Brunello L, Passera R, Dellacasa CM, Giaccone L, Audisio E, Ferrero D, D'Ardia S, Allione B, Aydin S, Festuccia M, Lia G, Crisà E, Maffini E, Butera S, Busca A, Bruno B. Haplo-identical allografting with post-transplant cyclophosphamide in high-risk patients. Ann Hematol 2018;97:2205-15. [PMID: 29987350 DOI: 10.1007/s00277-018-3433-3] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
|
| 128 |
Adachi Y, Ukai S, Sagou K, Fukushima N, Ozeki K, Kohno A. Promising Outcome of Umbilical Cord Blood Transplantation in Patients with Multiple Comorbidities. Biology of Blood and Marrow Transplantation 2018;24:1455-62. [DOI: 10.1016/j.bbmt.2018.02.013] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.4] [Reference Citation Analysis]
|
| 129 |
Jaiswal SR, Bhakuni P, Joy A, Murli N, Rajoreya A, Chakrabarti A, Chakrabarti S. Higher CD45RA+ Regulatory T Cells in the Graft Improves Outcome in Younger Patients Undergoing T Cell-Replete Haploidentical Transplantation: Where Donor Age Matters. Biol Blood Marrow Transplant 2018;24:2025-33. [PMID: 29906568 DOI: 10.1016/j.bbmt.2018.06.003] [Cited by in Crossref: 17] [Cited by in F6Publishing: 17] [Article Influence: 3.4] [Reference Citation Analysis]
|
| 130 |
Fuerst D, Frank S, Mueller C, Beelen DW, Schetelig J, Niederwieser D, Finke J, Bunjes D, Kröger N, Neuchel C, Tsamadou C, Schrezenmeier H, Beyersmann J, Mytilineos J. Competing-risk outcomes after hematopoietic stem cell transplantation from the perspective of time-dependent effects. Haematologica 2018;103:1527-34. [PMID: 29880610 DOI: 10.3324/haematol.2017.183012] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.6] [Reference Citation Analysis]
|
| 131 |
Ortí G, Sanz J, García-cadenas I, Sánchez-ortega I, Alonso L, Jiménez MJ, Sisinni L, Azqueta C, Salamero O, Badell I, Ferra C, de Heredia CD, Parody R, Sanz MA, Sierra J, Piñana JL, Querol S, Valcárcel D. Analysis of relapse after transplantation in acute leukemia: A comparative on second allogeneic hematopoietic cell transplantation and donor lymphocyte infusions. Experimental Hematology 2018;62:24-32. [DOI: 10.1016/j.exphem.2018.03.002] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 1.8] [Reference Citation Analysis]
|
| 132 |
Hueso T, Gauthier J, Joncquel Chevalier-Curt M, Magro L, Coiteux V, Dulery R, Carpentier B, Labreuche J, Damaj G, Yakoub-Agha I, Seguy D. Association Between Low Plasma Level of Citrulline Before Allogeneic Hematopoietic Cell Transplantation and Severe Gastrointestinal Graft vs Host Disease. Clin Gastroenterol Hepatol 2018;16:908-917.e2. [PMID: 29258901 DOI: 10.1016/j.cgh.2017.12.024] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.2] [Reference Citation Analysis]
|
| 133 |
Park H, Lee YJ, Shin S, Lee J, Park S, Kim I, Moon J, Lee H, Jang JH, Yoon S, Koh Y. Which donor is better when a matched donor is not available domestically? Comparison of outcomes of allogeneic stem cell transplantation with haploidentical and international donors in a homogenous ethnic population. Leukemia Research 2018;69:31-8. [DOI: 10.1016/j.leukres.2018.04.002] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 134 |
Hill JA, Pergam SA, Cox E, Xie H, Leisenring WM, Boeckh M, Delaney C, Milano F. A Modified Intensive Strategy to Prevent Cytomegalovirus Disease in Seropositive Umbilical Cord Blood Transplantation Recipients. Biol Blood Marrow Transplant 2018;24:2094-100. [PMID: 29753836 DOI: 10.1016/j.bbmt.2018.05.008] [Cited by in Crossref: 16] [Cited by in F6Publishing: 16] [Article Influence: 3.2] [Reference Citation Analysis]
|
| 135 |
Shibasaki Y, Suwabe T, Katagiri T, Tanaka T, Ushiki T, Fuse K, Sato N, Yano T, Kuroha T, Hashimoto S, Narita M, Furukawa T, Sone H, Masuko M. Refinement of the Glasgow Prognostic Score as a pre-transplant risk assessment for allogeneic hematopoietic cell transplantation. Int J Hematol 2018;108:282-9. [DOI: 10.1007/s12185-018-2463-x] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.6] [Reference Citation Analysis]
|
| 136 |
McDonald MK, Culos KA, Gatwood KS, Prow C, Chen H, Savani BN, Byrne M, Kassim AA, Engelhardt BG, Jagasia M, Satyanarayana G. Defining Incidence and Risk Factors for Catheter-Associated Bloodstream Infections in an Outpatient Adult Hematopoietic Cell Transplantation Program. Biol Blood Marrow Transplant 2018;24:2081-7. [PMID: 29753159 DOI: 10.1016/j.bbmt.2018.04.031] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 137 |
Bergeron A, Chevret S, Peffault de Latour R, Chagnon K, de Margerie-Mellon C, Rivière F, Robin M, Mani J, Lorillon G, Socié G, Tazi A. Noninfectious lung complications after allogeneic haematopoietic stem cell transplantation. Eur Respir J 2018;51:1702617. [PMID: 29650555 DOI: 10.1183/13993003.02617-2017] [Cited by in Crossref: 42] [Cited by in F6Publishing: 43] [Article Influence: 8.4] [Reference Citation Analysis]
|
| 138 |
Sedhom R, Strair R, Carson JL. Bad Blood or Sick Patient? Biology of Blood and Marrow Transplantation 2018;24:884-6. [DOI: 10.1016/j.bbmt.2018.03.014] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
|
| 139 |
Mussetti A, De Philippis C, Carniti C, Bastos-Oreiro M, Gayoso J, Cieri N, Pennisi M, Ciceri F, Greco R, Peccatori J, Patriarca F, Mariotti J, Castagna L, Corradini P. CD3+ graft cell count influence on chronic GVHD in haploidentical allogeneic transplantation using post-transplant cyclophosphamide. Bone Marrow Transplant 2018;53:1522-31. [PMID: 29703966 DOI: 10.1038/s41409-018-0183-8] [Cited by in Crossref: 16] [Cited by in F6Publishing: 16] [Article Influence: 3.2] [Reference Citation Analysis]
|
| 140 |
Mo X, Zhang X, Xu L, Wang Y, Yan C, Chen H, Chen Y, Han W, Wang F, Wang J, Liu K, Huang X. Interferon-α salvage treatment is effective for patients with acute leukemia/myelodysplastic syndrome with unsatisfactory response to minimal residual disease-directed donor lymphocyte infusion after allogeneic hematopoietic stem cell transplantation. Front Med 2019;13:238-49. [DOI: 10.1007/s11684-017-0599-3] [Cited by in Crossref: 12] [Cited by in F6Publishing: 14] [Article Influence: 2.4] [Reference Citation Analysis]
|
| 141 |
Debals-Gonthier M, Siani C, Faucher C, Touzani R, Lemarié-Basset C, Chabannon C, Furst S, Devillier R, Harbi S, Castagna L, Caymaris L, Blaise D, Le Corroller Soriano AG. Cost-effectiveness analysis of haploidentical vs matched unrelated allogeneic hematopoietic stem cells transplantation in patients older than 55 years. Bone Marrow Transplant 2018;53:1096-104. [PMID: 29523885 DOI: 10.1038/s41409-018-0133-5] [Cited by in Crossref: 16] [Cited by in F6Publishing: 16] [Article Influence: 3.2] [Reference Citation Analysis]
|
| 142 |
DeFilipp Z, Troschel FM, Qualls DA, Li S, Kuklinski MW, Kempner ME, Hochberg E, Chen YB, El-Jawahri A, Fintelmann FJ. Evolution of Body Composition Following Autologous and Allogeneic Hematopoietic Cell Transplantation: Incidence of Sarcopenia and Association with Clinical Outcomes. Biol Blood Marrow Transplant 2018;24:1741-7. [PMID: 29496561 DOI: 10.1016/j.bbmt.2018.02.016] [Cited by in Crossref: 22] [Cited by in F6Publishing: 22] [Article Influence: 4.4] [Reference Citation Analysis]
|
| 143 |
Steckel NK, Groth C, Mikesch JH, Trenschel R, Ottinger H, Kordelas L, Mueller-Tidow C, Schliemann C, Reicherts C, Albring JC, Silling G, Schmidt E, Berdel WE, Lenz G, Ditschkowski M, Beelen DW, Stelljes M. High-dose melphalan-based sequential conditioning chemotherapy followed by allogeneic haematopoietic stem cell transplantation in adult patients with relapsed or refractory acute myeloid leukaemia. Br J Haematol 2018;180:840-53. [PMID: 29468631 DOI: 10.1111/bjh.15137] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 2.4] [Reference Citation Analysis]
|
| 144 |
Zuckerman T. Allogeneic transplant: does age still matter? Blood 2017;130:1079-80. [PMID: 28860325 DOI: 10.1182/blood-2017-07-795948] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 1.2] [Reference Citation Analysis]
|
| 145 |
Mccurdy SR, Fuchs EJ. Post-transplant Cyclophosphamide in Haploidentical Transplantation. Haploidentical Transplantation 2018. [DOI: 10.1007/978-3-319-54310-9_7] [Reference Citation Analysis]
|
| 146 |
Kennedy VE, Chen H, Savani BN, Greer J, Kassim AA, Engelhardt BG, Goodman S, Sengsayadeth S, Chinratanalab W, Jagasia M. Optimizing Antithymocyte Globulin Dosing for Unrelated Donor Allogeneic Hematopoietic Cell Transplantation Based on Recipient Absolute Lymphocyte Count. Biology of Blood and Marrow Transplantation 2018;24:150-5. [DOI: 10.1016/j.bbmt.2017.08.029] [Cited by in Crossref: 41] [Cited by in F6Publishing: 43] [Article Influence: 8.2] [Reference Citation Analysis]
|
| 147 |
Jaiswal SR, Bhakuni P, Joy A, Murli N, Bharadwaj P, Zaman S, Nedunchezian M, Chakrabarti S. Impact of Single-Dose Plerixafor as an Adjunct to Granulocyte Colony-Stimulating Factor-Based Peripheral Blood Stem Cell Mobilization on the Graft Composition and Outcome for T Cell-Replete Haploidentical Peripheral Blood Stem Cell Transplantation with Post-Transplantation Cyclophosphamide: A Comparative Study. Biol Blood Marrow Transplant 2018;24:542-8. [PMID: 29191663 DOI: 10.1016/j.bbmt.2017.11.014] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 1.3] [Reference Citation Analysis]
|
| 148 |
Okamoto S. Current indication for hematopoietic cell transplantation in adults. Hematology/Oncology and Stem Cell Therapy 2017;10:178-83. [DOI: 10.1016/j.hemonc.2017.05.007] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 1.7] [Reference Citation Analysis]
|
| 149 |
Forcina A, Rancoita PM, Marcatti M, Greco R, Lupo-stanghellini MT, Carrabba M, Marasco V, Di Serio C, Bernardi M, Peccatori J, Corti C, Bondanza A, Ciceri F. A New Clinicobiological Scoring System for the Prediction of Infection-Related Mortality and Survival after Allogeneic Hematopoietic Stem Cell Transplantation. Biology of Blood and Marrow Transplantation 2017;23:2151-8. [DOI: 10.1016/j.bbmt.2017.08.010] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.8] [Reference Citation Analysis]
|
| 150 |
Hegde A, Murthy HS. Frailty: the missing piece of the pre- hematopoietic cell transplantation assessment? Bone Marrow Transplant 2018;53:3-10. [PMID: 29084201 DOI: 10.1038/bmt.2017.192] [Cited by in Crossref: 18] [Cited by in F6Publishing: 21] [Article Influence: 3.0] [Reference Citation Analysis]
|
| 151 |
Paviglianiti A, Ruggeri A, Volt F, Sanz G, Milpied N, Furst S, Esquirol A, Arcese W, Picardi A, Ferra C, Ifrah N, Bourhis JH, Raj K, von dem Borne PA, Sica S, Menard A, Bloor A, Kenzey C, Gluckman E, Rocha V. Evaluation of a disease risk index for adult patients undergoing umbilical cord blood transplantation for haematological malignancies. Br J Haematol 2017;179:790-801. [DOI: 10.1111/bjh.14962] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 152 |
McCurdy SR, Kanakry CG, Tsai HL, Kasamon YL, Showel MM, Bolaños-Meade J, Huff CA, Borrello I, Matsui WH, Brodsky RA, Ambinder RF, Bettinotti MP, Fuchs EJ, Rosner GL, Jones RJ, Luznik L. Grade II Acute Graft-versus-Host Disease and Higher Nucleated Cell Graft Dose Improve Progression-Free Survival after HLA-Haploidentical Transplant with Post-Transplant Cyclophosphamide. Biol Blood Marrow Transplant 2018;24:343-52. [PMID: 29055682 DOI: 10.1016/j.bbmt.2017.10.023] [Cited by in Crossref: 53] [Cited by in F6Publishing: 54] [Article Influence: 8.8] [Reference Citation Analysis]
|
| 153 |
Gerull S, Denhaerynck K, Chalandon Y, Halter JP, Kirsch M, Kiss A, Schanz U, Vu DL, De Geest S, Passweg J. Lack of association between relationship status and clinical outcome in allogeneic stem cell transplantation-the Swiss Transplant Cohort Study. Bone Marrow Transplant 2017;52:1686-8. [PMID: 28991251 DOI: 10.1038/bmt.2017.204] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.5] [Reference Citation Analysis]
|
| 154 |
Lee CJ, Savani BN, Mohty M, Labopin M, Ruggeri A, Schmid C, Baron F, Esteve J, Gorin NC, Giebel S, Ciceri F, Nagler A. Haploidentical hematopoietic cell transplantation for adult acute myeloid leukemia: a position statement from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation. Haematologica 2017;102:1810-22. [PMID: 28883081 DOI: 10.3324/haematol.2017.176107] [Cited by in Crossref: 51] [Cited by in F6Publishing: 55] [Article Influence: 8.5] [Reference Citation Analysis]
|
| 155 |
Modi D, Deol A, Kim S, Ayash L, Alavi A, Ventimiglia M, Bhutani D, Ratanatharathorn V, Uberti JP. Age does not adversely influence outcomes among patients older than 60 years who undergo allogeneic hematopoietic stem cell transplant for AML and myelodysplastic syndrome. Bone Marrow Transplant 2017;52:1530-6. [PMID: 28869613 DOI: 10.1038/bmt.2017.182] [Cited by in Crossref: 17] [Cited by in F6Publishing: 17] [Article Influence: 2.8] [Reference Citation Analysis]
|
| 156 |
Mehdi A, Rybicki L, Mossad S, Yurch M, Sekeres M, Gerds AT, Jagadeesh D, Hamilton B, Liu H, Dean R, Pohlman B, Sobecks R, Andresen S, Kalaycio M, Bolwell BJ, Majhail NS, Copelan E, Hill BT. Impact of cigarette smoking on survival after myeloablative allogeneic hematopoietic stem cell transplantation and contribution of invasive fungal infection. Bone Marrow Transplant 2017;52:1665-7. [DOI: 10.1038/bmt.2017.184] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 157 |
Tong J, Xuan L, Sun Y, Huang D, Liu H, Zheng C, Zhu X, Tang B, Song K, Zhang X, Zhang L, Yao W, Lin D, Liu Q, Sun Z. Umbilical Cord Blood Transplantation without Antithymocyte Globulin Results in Similar Survival but Better Quality of Life Compared with Unrelated Peripheral Blood Stem Cell Transplantation for the Treatment of Acute Leukemia—A Retrospective Study in China. Biology of Blood and Marrow Transplantation 2017;23:1541-8. [DOI: 10.1016/j.bbmt.2017.05.004] [Cited by in Crossref: 13] [Cited by in F6Publishing: 11] [Article Influence: 2.2] [Reference Citation Analysis]
|
| 158 |
Broglie L, Helenowski I, Jennings LJ, Schafernak K, Duerst R, Schneiderman J, Tse W, Kletzel M, Chaudhury S. Early mixed T-cell chimerism is predictive of pediatric AML or MDS relapse after hematopoietic stem cell transplant. Pediatr Blood Cancer 2017;64. [PMID: 28266766 DOI: 10.1002/pbc.26493] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.2] [Reference Citation Analysis]
|
| 159 |
Bergeron A, Chevret S, Granata A, Chevallier P, Vincent L, Huynh A, Tabrizi R, Labussiere-Wallet H, Bernard M, Chantepie S, Bay JO, Thiebaut-Bertrand A, Thepot S, Contentin N, Fornecker LM, Maillard N, Risso K, Berceanu A, Blaise D, Peffault de La Tour R, Chien JW, Coiteux V, Socié G; ALLOZITHRO Study Investigators. Effect of Azithromycin on Airflow Decline-Free Survival After Allogeneic Hematopoietic Stem Cell Transplant: The ALLOZITHRO Randomized Clinical Trial. JAMA 2017;318:557-66. [PMID: 28787506 DOI: 10.1001/jama.2017.9938] [Cited by in Crossref: 75] [Cited by in F6Publishing: 74] [Article Influence: 12.5] [Reference Citation Analysis]
|
| 160 |
Potdar R, Varadi G, Fein J, Labopin M, Nagler A, Shouval R. Prognostic Scoring Systems in Allogeneic Hematopoietic Stem Cell Transplantation: Where Do We Stand? Biol Blood Marrow Transplant 2017;23:1839-46. [PMID: 28797781 DOI: 10.1016/j.bbmt.2017.07.028] [Cited by in Crossref: 22] [Cited by in F6Publishing: 25] [Article Influence: 3.7] [Reference Citation Analysis]
|
| 161 |
Mo X, Zhang X, Xu L, Wang Y, Yan C, Chen H, Chen Y, Han W, Wang F, Wang J, Liu K, Huang X. IFN-α Is Effective for Treatment of Minimal Residual Disease in Patients with Acute Leukemia after Allogeneic Hematopoietic Stem Cell Transplantation: Results of a Registry Study. Biology of Blood and Marrow Transplantation 2017;23:1303-10. [DOI: 10.1016/j.bbmt.2017.04.023] [Cited by in Crossref: 29] [Cited by in F6Publishing: 31] [Article Influence: 4.8] [Reference Citation Analysis]
|
| 162 |
Simonetta F, Masouridi-levrat S, Beauverd Y, Tsopra O, Tirefort Y, Koutsi A, Stephan C, Polchlopek-blasiak K, Pradier A, Dantin C, Ansari M, Roosnek E, Chalandon Y. Partial T-cell depletion improves the composite endpoint graft-versus-host disease-free, relapse-free survival after allogeneic hematopoietic stem cell transplantation. Leukemia & Lymphoma 2017;59:590-600. [DOI: 10.1080/10428194.2017.1344844] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
|
| 163 |
Getta BM, Devlin SM, Levine RL, Arcila ME, Mohanty AS, Zehir A, Tallman MS, Giralt SA, Roshal M. Multicolor Flow Cytometry and Multigene Next-Generation Sequencing Are Complementary and Highly Predictive for Relapse in Acute Myeloid Leukemia after Allogeneic Transplantation. Biol Blood Marrow Transplant 2017;23:1064-71. [PMID: 28315400 DOI: 10.1016/j.bbmt.2017.03.017] [Cited by in Crossref: 91] [Cited by in F6Publishing: 94] [Article Influence: 15.2] [Reference Citation Analysis]
|
| 164 |
Schmidt E, Mikesch J, Groth C, Schliemann C, Lenz G, Berdel WE, Stelljes M. Allogene Transplantation in der Behandlung der akuten Leukämien. Onkologe 2017;23:543-549. [DOI: 10.1007/s00761-017-0234-6] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
|
| 165 |
Wang Y, Wu DP, Liu QF, Xu LP, Liu KY, Zhang XH, Xu Y, Huang F, Huang XJ. Donor and recipient age, gender and ABO incompatibility regardless of donor source: validated criteria for donor selection for haematopoietic transplants. Leukemia 2018;32:492-8. [PMID: 28642591 DOI: 10.1038/leu.2017.199] [Cited by in Crossref: 40] [Cited by in F6Publishing: 44] [Article Influence: 6.7] [Reference Citation Analysis]
|
| 166 |
Kharfan-Dabaja MA, Komrokji RS, Zhang Q, Kumar A, Tsalatsanis A, Perkins J, Nishihori T, Field T, Al Ali N, Mishra A, Sallman D, Salem KZ, Zhang L, Moscinski L, Fernandez HF, Lancet J, List A, Anasetti C, Padron E. TP53 and IDH2 Somatic Mutations Are Associated With Inferior Overall Survival After Allogeneic Hematopoietic Cell Transplantation for Myelodysplastic Syndrome. Clin Lymphoma Myeloma Leuk 2017;17:753-8. [PMID: 28687222 DOI: 10.1016/j.clml.2017.06.003] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 2.3] [Reference Citation Analysis]
|
| 167 |
Giralt SA. Biology: Critical Components of Hematopoietic Cell Transplantation. Hematopoietic Cell Transplants 2017. [DOI: 10.1017/9781316335727.004] [Reference Citation Analysis]
|
| 168 |
Recipient Selection for Hematopoietic Cell Transplantation. Hematopoietic Cell Transplants 2017. [DOI: 10.1017/9781316335727.005] [Reference Citation Analysis]
|
| 169 |
Finazzi MC, Lussana F, Salmoiraghi S, Spinelli O, Rambaldi A. Detection of driver and subclonal mutations in myelofibrosis: clinical impact on pharmacologic and transplant based treatment strategies. Expert Rev Hematol 2017;10:627-36. [PMID: 28504024 DOI: 10.1080/17474086.2017.1331125] [Reference Citation Analysis]
|
| 170 |
Nakane T, Nakamae M, Koh H, Nishimoto M, Nakashima Y, Hirose A, Hino M, Nakamae H. Autonomic Nervous System Pretransplant Malfunction Is a Powerful Predictor of Survival After Allogeneic Hematopoietic Cell Transplantation. Transplantation 2017;101:2801-9. [PMID: 28505024 DOI: 10.1097/TP.0000000000001813] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
|
| 171 |
Chee L, Tacey M, Lim B, Lim A, Szer J, Ritchie D. Pre-transplant ferritin, albumin and haemoglobin are predictive of survival outcome independent of disease risk index following allogeneic stem cell transplantation. Bone Marrow Transplant 2017;52:870-7. [DOI: 10.1038/bmt.2017.51] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 2.2] [Reference Citation Analysis]
|
| 172 |
Elsawy M, Sorror ML. Risk-benefit assessment in allogeneic hematopoietic transplant. Clinical Manual of Blood and Bone Marrow Transplantation 2017. [DOI: 10.1002/9781119095491.ch3] [Reference Citation Analysis]
|
| 173 |
Ertz-archambault N, Kosiorek H, Slack JL, Lonzo ML, Greipp PT, Khera N, Kelemen K. Cytogenetic Evolution in Myeloid Neoplasms at Relapse after Allogeneic Hematopoietic Cell Transplantation: Association with Previous Chemotherapy and Effect on Survival. Biology of Blood and Marrow Transplantation 2017;23:782-9. [DOI: 10.1016/j.bbmt.2017.02.003] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 174 |
Decook L, Chang Y, Slack J, Gastineau D, Leis J, Noel P, Palmer J, Sproat L, Sorror M, Khera N. Association of hematopoietic cell transplantation-specific comorbidity index with resource utilization after allogeneic transplantation. Bone Marrow Transplant 2017;52:998-1002. [DOI: 10.1038/bmt.2017.70] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.8] [Reference Citation Analysis]
|
| 175 |
Kanate AS, Hari PN, Pasquini MC, Visotcky A, Ahn KW, Boyd J, Guru Murthy GS, Rizzo JD, Saber W, Drobyski W, Michaelis L, Atallah E, Carlson KS, D'Souza A, Fenske TS, Cumpston A, Bunner P, Craig M, Horowitz MM, Hamadani M. Recipient Immune Modulation with Atorvastatin for Acute Graft-versus-Host Disease Prophylaxis after Allogeneic Transplantation. Biol Blood Marrow Transplant 2017;23:1295-302. [PMID: 28412518 DOI: 10.1016/j.bbmt.2017.04.009] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.2] [Reference Citation Analysis]
|
| 176 |
Yamasaki S, Suzuki R, Hatano K, Fukushima K, Iida H, Morishima S, Suehiro Y, Fukuda T, Uchida N, Uchiyama H, Ikeda H, Yokota A, Tsukasaki K, Yamaguchi H, Kuroda J, Nakamae H, Adachi Y, Matsuoka KI, Nakamura Y, Atsuta Y, Suzumiya J. Therapy-related acute myeloid leukemia and myelodysplastic syndrome after hematopoietic cell transplantation for lymphoma. Bone Marrow Transplant 2017;52:969-76. [PMID: 28368379 DOI: 10.1038/bmt.2017.52] [Cited by in Crossref: 12] [Cited by in F6Publishing: 13] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 177 |
Bachegowda LS, Saliba RM, Ramlal R, Kongtim P, Chen J, Rondon G, Wallis W, Alousi A, Ahmed S, Hosing CM, Parmar S, Qazilbash M, Khouri IF, Bashir Q, Oran B, Popat U, Shpall EJ, Marin D, Rezvani K, Kebriaei P, Champlin RE, Ciurea SO. Predictive model for survival in patients with AML/MDS receiving haploidentical stem cell transplantation. Blood 2017;129:3031-3. [PMID: 28351938 DOI: 10.1182/blood-2017-02-766154] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 1.2] [Reference Citation Analysis]
|
| 178 |
Chang YJ, Wang Y, Mo XD, Zhang XH, Xu LP, Yan CH, Chen H, Chen YH, Chen Y, Han W, Wang FR, Wang JZ, Liu KY, Huang XJ. Optimal dose of rabbit thymoglobulin in conditioning regimens for unmanipulated, haploidentical, hematopoietic stem cell transplantation: Long-term outcomes of a prospective randomized trial. Cancer 2017;123:2881-92. [PMID: 28301690 DOI: 10.1002/cncr.30540] [Cited by in Crossref: 38] [Cited by in F6Publishing: 42] [Article Influence: 6.3] [Reference Citation Analysis]
|
| 179 |
Mo XD, Zhang XH, Xu LP, Wang Y, Yan CH, Chen H, Chen YH, Han W, Wang FR, Wang JZ, Liu KY, Huang XJ. Comparison of outcomes after donor lymphocyte infusion with or without prior chemotherapy for minimal residual disease in acute leukemia/myelodysplastic syndrome after allogeneic hematopoietic stem cell transplantation. Ann Hematol 2017;96:829-38. [PMID: 28285386 DOI: 10.1007/s00277-017-2960-7] [Cited by in Crossref: 27] [Cited by in F6Publishing: 30] [Article Influence: 4.5] [Reference Citation Analysis]
|
| 180 |
Cheng GS. Pulmonary Function and Pretransplant Evaluation of the Hematopoietic Cell Transplant Candidate. Clin Chest Med 2017;38:307-16. [PMID: 28477641 DOI: 10.1016/j.ccm.2016.12.014] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.2] [Reference Citation Analysis]
|
| 181 |
Preussler JM, Meyer CL, Mau LW, Majhail NS, Denzen EM, Edsall KC, Farnia SH, Saber W, Burns LJ, Vanness DJ. Healthcare Costs and Utilization for Patients Age 50 to 64 Years with Acute Myeloid Leukemia Treated with Chemotherapy or with Chemotherapy and Allogeneic Hematopoietic Cell Transplantation. Biol Blood Marrow Transplant 2017;23:1021-8. [PMID: 28263920 DOI: 10.1016/j.bbmt.2017.02.017] [Cited by in Crossref: 26] [Cited by in F6Publishing: 20] [Article Influence: 4.3] [Reference Citation Analysis]
|
| 182 |
Zhou W, Sultana R, Diong C, Goh YT, Gopalakrishnan S, Ho A, Hwang W, Koh LP, Koh M, Loh Y, Tan P, Linn YC. Long-term renal outcome after allogeneic hemopoietic stem cell transplant: A comprehensive analysis of risk factors in an Asian patient population. Clin Transplant 2017;31. [PMID: 28135776 DOI: 10.1111/ctr.12920] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
|
| 183 |
Sakellari I, Mallouri D, Gavriilaki E, Batsis I, Kaliou M, Constantinou V, Papalexandri A, Lalayanni C, Vadikolia C, Athanasiadou A, Yannaki E, Sotiropoulos D, Smias C, Anagnostopoulos A. Survival Advantage and Comparable Toxicity in Reduced-Toxicity Treosulfan-Based versus Reduced-Intensity Busulfan-Based Conditioning Regimen in Myelodysplastic Syndrome and Acute Myeloid Leukemia Patients after Allogeneic Hematopoietic Cell Transplantation. Biology of Blood and Marrow Transplantation 2017;23:445-51. [DOI: 10.1016/j.bbmt.2016.11.023] [Cited by in Crossref: 21] [Cited by in F6Publishing: 22] [Article Influence: 3.5] [Reference Citation Analysis]
|
| 184 |
Haen SP, Groh C, Schumm M, Backert L, Löffler MW, Federmann B, Faul C, Dörfel D, Vogel W, Handgretinger R, Kanz L, Bethge WA. Haploidentical hematopoietic cell transplantation using in vitro T cell depleted grafts as salvage therapy in patients with disease relapse after prior allogeneic transplantation. Ann Hematol 2017;96:817-27. [PMID: 28247058 DOI: 10.1007/s00277-017-2941-x] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 2.2] [Reference Citation Analysis]
|
| 185 |
Ji SM, Bao XB, Lu J, Ma X, Tao T, Sun AN, Wu DP, Xue SL. Protective Effect of Rituximab in Chronic Graft-Versus-Host Disease Occurrence in Allogeneic Transplant patients with Epstein Barr Virus Viremia. Indian J Hematol Blood Transfus 2017;33:525-33. [PMID: 29075063 DOI: 10.1007/s12288-017-0783-2] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
|
| 186 |
Feher A, Kampaktsis PN, Parameswaran R, Stein EM, Steingart R, Gupta D. Aspirin Is Associated with Improved Survival in Severely Thrombocytopenic Cancer Patients with Acute Myocardial Infarction. Oncologist 2017;22:213-21. [PMID: 28159866 DOI: 10.1634/theoncologist.2016-0110] [Cited by in Crossref: 16] [Cited by in F6Publishing: 17] [Article Influence: 2.7] [Reference Citation Analysis]
|
| 187 |
de Witte T, Bowen D, Robin M, Malcovati L, Niederwieser D, Yakoub-Agha I, Mufti GJ, Fenaux P, Sanz G, Martino R, Alessandrino EP, Onida F, Symeonidis A, Passweg J, Kobbe G, Ganser A, Platzbecker U, Finke J, van Gelder M, van de Loosdrecht AA, Ljungman P, Stauder R, Volin L, Deeg HJ, Cutler C, Saber W, Champlin R, Giralt S, Anasetti C, Kröger N. Allogeneic hematopoietic stem cell transplantation for MDS and CMML: recommendations from an international expert panel. Blood 2017;129:1753-62. [PMID: 28096091 DOI: 10.1182/blood-2016-06-724500] [Cited by in Crossref: 201] [Cited by in F6Publishing: 212] [Article Influence: 33.5] [Reference Citation Analysis]
|
| 188 |
Moy RH, Huffman AP, Richman LP, Crisalli L, Wang XK, Hoxie JA, Mick R, Emerson SG, Zhang Y, Vonderheide RH, Porter DL, Reshef R. Clinical and immunologic impact of CCR5 blockade in graft-versus-host disease prophylaxis. Blood 2017;129:906-16. [PMID: 28057639 DOI: 10.1182/blood-2016-08-735076] [Cited by in Crossref: 47] [Cited by in F6Publishing: 48] [Article Influence: 7.8] [Reference Citation Analysis]
|
| 189 |
Törlén J, Remberger M, Le Blanc K, Ljungman P, Mattsson J. Impact of Pretransplantation Indices in Hematopoietic Stem Cell Transplantation: Knowledge of Center-Specific Outcome Data Is Pivotal before Making Index-Based Decisions. Biol Blood Marrow Transplant 2017;23:677-83. [PMID: 28063962 DOI: 10.1016/j.bbmt.2017.01.003] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 190 |
Kumar AJ, Gimotty PA, Gelfand JM, Buck G, Rowe JM, Goldstone AH, Fielding A, Marks DI, Litzow M, Paietta E, Lazarus HM, Tallman MS, Luger SM, Loren AW. Delays in postremission chemotherapy for Philadelphia chromosome negative acute lymphoblastic leukemia are associated with inferior outcomes in patients who undergo allogeneic transplant: An analysis from ECOG 2993/MRC UK ALLXII. Am J Hematol 2016;91:1107-12. [PMID: 27468137 DOI: 10.1002/ajh.24497] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 191 |
Maka VV, Koh LP, Diong C, Goh YT, Gopalakrishnan S, Ho A, Hwang W, Koh M, Lim F, Lim ZY, Loh Y, Poon M, Del Rosario DR, Tai BC, Tan LK, Tan P, Linn YC. An exploration of the applicability of the refined disease risk index and its integration with other independent risk factors for individualized prognostication. Bone Marrow Transplant 2017;52:363-71. [PMID: 27797364 DOI: 10.1038/bmt.2016.286] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.4] [Reference Citation Analysis]
|
| 192 |
Nassereddine S, Nishihori T, Padron E, Mahfouz R, Bazarbachi A, Komrokji RS, Kharfan-Dabaja MA. Integrating Genomics in Myelodysplastic Syndrome to Predict Outcomes After Allogeneic Hematopoietic Cell Transplantation. Clin Lymphoma Myeloma Leuk 2017;17:7-13. [PMID: 27771290 DOI: 10.1016/j.clml.2016.09.005] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.4] [Reference Citation Analysis]
|
| 193 |
Politikos I, T Kim H, Karantanos T, Brown J, McDonough S, Li L, Cutler C, Antin JH, Ballen KK, Ritz J, Boussiotis VA. Angiogenic Factors Correlate with T Cell Immune Reconstitution and Clinical Outcomes after Double-Unit Umbilical Cord Blood Transplantation in Adults. Biol Blood Marrow Transplant 2017;23:103-12. [PMID: 27777141 DOI: 10.1016/j.bbmt.2016.10.013] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.4] [Reference Citation Analysis]
|
| 194 |
McCurdy SR, Kasamon YL, Kanakry CG, Bolaños-Meade J, Tsai HL, Showel MM, Kanakry JA, Symons HJ, Gojo I, Smith BD, Bettinotti MP, Matsui WH, Dezern AE, Huff CA, Borrello I, Pratz KW, Gladstone DE, Swinnen LJ, Brodsky RA, Levis MJ, Ambinder RF, Fuchs EJ, Rosner GL, Jones RJ, Luznik L. Comparable composite endpoints after HLA-matched and HLA-haploidentical transplantation with post-transplantation cyclophosphamide. Haematologica 2017;102:391-400. [PMID: 27846611 DOI: 10.3324/haematol.2016.144139] [Cited by in Crossref: 121] [Cited by in F6Publishing: 129] [Article Influence: 17.3] [Reference Citation Analysis]
|
| 195 |
Modi D, Jang H, Kim S, Deol A, Ayash L, Bhutani D, Lum LG, Ratanatharathorn V, Manasa R, Mellert K, Uberti JP. Incidence, etiology, and outcome of pleural effusions in allogeneic hematopoietic stem cell transplantation. Am J Hematol 2016;91:E341-7. [PMID: 27238902 DOI: 10.1002/ajh.24435] [Cited by in Crossref: 15] [Cited by in F6Publishing: 17] [Article Influence: 2.1] [Reference Citation Analysis]
|
| 196 |
Knight JM, Syrjala KL, Majhail NS, Martens M, Le-Rademacher J, Logan BR, Lee SJ, Jacobsen PB, Wood WA, Jim HSL, Wingard JR, Horowitz MM, Abidi MH, Fei M, Rawls L, Rizzo JD. Patient-Reported Outcomes and Socioeconomic Status as Predictors of Clinical Outcomes after Hematopoietic Stem Cell Transplantation: A Study from the Blood and Marrow Transplant Clinical Trials Network 0902 Trial. Biol Blood Marrow Transplant 2016;22:2256-63. [PMID: 27565521 DOI: 10.1016/j.bbmt.2016.08.016] [Cited by in Crossref: 15] [Cited by in F6Publishing: 17] [Article Influence: 2.1] [Reference Citation Analysis]
|
| 197 |
Carapito R, Jung N, Kwemou M, Untrau M, Michel S, Pichot A, Giacometti G, Macquin C, Ilias W, Morlon A, Kotova I, Apostolova P, Schmitt-Graeff A, Cesbron A, Gagne K, Oudshoorn M, van der Holt B, Labalette M, Spierings E, Picard C, Loiseau P, Tamouza R, Toubert A, Parissiadis A, Dubois V, Lafarge X, Maumy-Bertrand M, Bertrand F, Vago L, Ciceri F, Paillard C, Querol S, Sierra J, Fleischhauer K, Nagler A, Labopin M, Inoko H, von dem Borne PA, Kuball J, Ota M, Katsuyama Y, Michallet M, Lioure B, Peffault de Latour R, Blaise D, Cornelissen JJ, Yakoub-Agha I, Claas F, Moreau P, Milpied N, Charron D, Mohty M, Zeiser R, Socié G, Bahram S. Matching for the nonconventional MHC-I MICA gene significantly reduces the incidence of acute and chronic GVHD. Blood 2016;128:1979-86. [PMID: 27549307 DOI: 10.1182/blood-2016-05-719070] [Cited by in Crossref: 50] [Cited by in F6Publishing: 50] [Article Influence: 7.1] [Reference Citation Analysis]
|
| 198 |
Gaballa S, Ge I, El Fakih R, Brammer JE, Kongtim P, Tomuleasa C, Wang SA, Lee D, Petropoulos D, Cao K, Rondon G, Chen J, Hammerstrom A, Lombardi L, Alatrash G, Korbling M, Oran B, Kebriaei P, Ahmed S, Shah N, Rezvani K, Marin D, Bashir Q, Alousi A, Nieto Y, Qazilbash M, Hosing C, Popat U, Shpall EJ, Khouri I, Champlin RE, Ciurea SO. Results of a 2-arm, phase 2 clinical trial using post-transplantation cyclophosphamide for the prevention of graft-versus-host disease in haploidentical donor and mismatched unrelated donor hematopoietic stem cell transplantation. Cancer 2016;122:3316-26. [PMID: 27404668 DOI: 10.1002/cncr.30180] [Cited by in Crossref: 62] [Cited by in F6Publishing: 66] [Article Influence: 8.9] [Reference Citation Analysis]
|
| 199 |
Haen SP, Pham M, Faul C, Dörfel D, Vogel W, Kanz L, Bethge WA. Allogeneic hematopoietic cell transplantation in patients ⩾70 years: which patients may benefit? Blood Cancer J 2016;6:e443. [PMID: 27391575 DOI: 10.1038/bcj.2016.54] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 0.1] [Reference Citation Analysis]
|
| 200 |
Kennedy VE, Savani BN, Greer JP, Kassim AA, Engelhardt BG, Goodman SA, Sengsayadeth S, Chinratanalab W, Jagasia M. Reduced-Intensity Conditioning with Fludarabine, Cyclophosphamide, and Rituximab Is Associated with Improved Outcomes Compared with Fludarabine and Busulfan after Allogeneic Stem Cell Transplantation for B Cell Malignancies. Biol Blood Marrow Transplant 2016;22:1801-7. [PMID: 27377900 DOI: 10.1016/j.bbmt.2016.06.029] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 0.7] [Reference Citation Analysis]
|
| 201 |
Kim HT, Zhang MJ, Woolfrey AE, St Martin A, Chen J, Saber W, Perales MA, Armand P, Eapen M. Donor and recipient sex in allogeneic stem cell transplantation: what really matters. Haematologica 2016;101:1260-6. [PMID: 27354023 DOI: 10.3324/haematol.2016.147645] [Cited by in Crossref: 36] [Cited by in F6Publishing: 42] [Article Influence: 5.1] [Reference Citation Analysis]
|
| 202 |
Brunner AM, Fathi AT, Chen YB. Life after transplant: are we becoming high maintenance in AML? Bone Marrow Transplant 2016;51:1423-30. [DOI: 10.1038/bmt.2016.160] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 1.7] [Reference Citation Analysis]
|
| 203 |
Blennow O, Remberger M, Törlén J, Szakos A, Ljungman P, Mattsson J. Risk Factors for Invasive Mold Infections and Implications for Choice of Prophylaxis after Allogeneic Stem Cell Transplantation. Biol Blood Marrow Transplant 2016;22:1684-9. [PMID: 27311967 DOI: 10.1016/j.bbmt.2016.06.008] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 1.1] [Reference Citation Analysis]
|
| 204 |
Pohlen M, Groth C, Sauer T, Görlich D, Mesters R, Schliemann C, Lenz G, Müller-Tidow C, Büchner T, Berdel WE, Stelljes M. Outcome of allogeneic stem cell transplantation for AML and myelodysplastic syndrome in elderly patients (⩾60 years). Bone Marrow Transplant 2016;51:1441-8. [PMID: 27295269 DOI: 10.1038/bmt.2016.156] [Cited by in Crossref: 26] [Cited by in F6Publishing: 28] [Article Influence: 3.7] [Reference Citation Analysis]
|
| 205 |
Kim SY, Lee H, Han MS, Shim H, Eom HS, Park B, Kong SY. Post-Transplantation Natural Killer Cell Count: A Predictor of Acute Graft-Versus-Host Disease and Survival Outcomes After Allogeneic Hematopoietic Stem Cell Transplantation. Clin Lymphoma Myeloma Leuk 2016;16:527-535.e2. [PMID: 27375156 DOI: 10.1016/j.clml.2016.06.013] [Cited by in Crossref: 14] [Cited by in F6Publishing: 16] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 206 |
Elsawy M, Sorror ML. Up-to-date tools for risk assessment before allogeneic hematopoietic cell transplantation. Bone Marrow Transplant 2016;51:1283-300. [PMID: 27272454 DOI: 10.1038/bmt.2016.141] [Cited by in Crossref: 53] [Cited by in F6Publishing: 55] [Article Influence: 7.6] [Reference Citation Analysis]
|
| 207 |
El Cheikh J, Otrock ZK, Qannus AA, Kharfan-dabaja MA, Bazarbachi A. Risk-Adapted Approach to HLA-Matched Sibling Hematopoietic Cell Allografting: Impact of Adjusting Conditioning Intensity and Integrating Post-Transplant Therapeutic Interventions. Clinical Lymphoma Myeloma and Leukemia 2016;16:304-10. [DOI: 10.1016/j.clml.2016.01.005] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 1.3] [Reference Citation Analysis]
|
| 208 |
Chang YJ, Xu LP, Wang Y, Zhang XH, Chen H, Chen YH, Wang FR, Han W, Sun YQ, Yan CH, Tang FF, Mo XD, Liu KY, Huang XJ. Controlled, Randomized, Open-Label Trial of Risk-Stratified Corticosteroid Prevention of Acute Graft-Versus-Host Disease After Haploidentical Transplantation. J Clin Oncol 2016;34:1855-63. [PMID: 27091717 DOI: 10.1200/JCO.2015.63.8817] [Cited by in Crossref: 63] [Cited by in F6Publishing: 68] [Article Influence: 9.0] [Reference Citation Analysis]
|
| 209 |
Shaffer BC, Ahn KW, Hu ZH, Nishihori T, Malone AK, Valcárcel D, Grunwald MR, Bacher U, Hamilton B, Kharfan-Dabaja MA, Saad A, Cutler C, Warlick E, Reshef R, Wirk BM, Sabloff M, Fasan O, Gerds A, Marks D, Olsson R, Wood WA, Costa LJ, Miller AM, Cortes J, Daly A, Kindwall-Keller TL, Kamble R, Rizzieri DA, Cahn JY, Gale RP, William B, Litzow M, Wiernik PH, Liesveld J, Savani BN, Vij R, Ustun C, Copelan E, Popat U, Kalaycio M, Maziarz R, Alyea E, Sobecks R, Pavletic S, Tallman M, Saber W. Scoring System Prognostic of Outcome in Patients Undergoing Allogeneic Hematopoietic Cell Transplantation for Myelodysplastic Syndrome. J Clin Oncol 2016;34:1864-71. [PMID: 27044940 DOI: 10.1200/JCO.2015.65.0515] [Cited by in Crossref: 48] [Cited by in F6Publishing: 51] [Article Influence: 6.9] [Reference Citation Analysis]
|
| 210 |
Ramaswamy S, Jain S, Ravindran V. Hematopoietic stem cell transplantation for auto immune rheumatic diseases. World J Transplant 2016; 6(1): 199-205 [PMID: 27011918 DOI: 10.5500/wjt.v6.i1.199] [Cited by in CrossRef: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.7] [Reference Citation Analysis]
|
| 211 |
Hobbs GS, Kaur N, Hilden P, Ponce D, Cho C, Castro-Malaspina HR, Giralt S, Goldberg JD, Jakubowski AA, Papadopoulos EB, Sauter C, Koehne G, Yahalom J, Delvin S, Barker JN, Perales MA. A novel reduced intensity conditioning regimen for patients with high-risk hematological malignancies undergoing allogeneic stem cell transplantation. Bone Marrow Transplant 2016;51:1010-2. [PMID: 26974271 DOI: 10.1038/bmt.2016.36] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 212 |
De La Serna J, Sanz J, Bermúdez A, Cabrero M, Serrano D, Vallejo C, Gómez V, Moraleda JM, Perez SG, Caballero MD, Conde E, Lahuerta JJ, Sanz G. Toxicity and efficacy of busulfan and fludarabine myeloablative conditioning for HLA-identical sibling allogeneic hematopoietic cell transplantation in AML and MDS. Bone Marrow Transplant 2016;51:961-6. [PMID: 26950372 DOI: 10.1038/bmt.2016.42] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 213 |
Beauverd Y, Roosnek E, Tirefort Y, Dantin C, Ansari M, Tsopra O, Masouridi-levrat S, Chalandon Y. Outcome of hematopoietic stem cell transplantation is similar for patients with a partial in vitro T-cell-depleted graft compared with a non-T-cell-depleted graft when stratified by the refined disease risk index. Bone Marrow Transplant 2016;51:955-60. [DOI: 10.1038/bmt.2016.34] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.7] [Reference Citation Analysis]
|
| 214 |
Apperley J, Niederwieser D, Huang X, Nagler A, Fuchs E, Szer J, Kodera Y. Reprint of: Haploidentical Hematopoietic Stem Cell Transplantation: A Global Overview Comparing Asia, the European Union, and the United States. Biology of Blood and Marrow Transplantation 2016;22:S15-8. [DOI: 10.1016/j.bbmt.2016.01.006] [Cited by in Crossref: 20] [Cited by in F6Publishing: 19] [Article Influence: 2.9] [Reference Citation Analysis]
|
| 215 |
Wanquet A, Crocchiolo R, Furst S, Granata A, Faucher C, Devillier R, Harbi S, Lemarie C, Calmels B, Vey N, Weiller PJ, Chabannon C, Castagna L, Blaise D, El-Cheikh J. The efficacy and safety of a new reduced-toxicity conditioning with 4 days of once-daily 100 mg/m(2) intravenous busulfan associated with fludarabine and antithymocyte globulins prior to allogeneic stem cell transplantation in patients with high-risk myelodysplastic syndrome or acute leukemia. Leuk Lymphoma 2016;57:2315-20. [PMID: 26885686 DOI: 10.3109/10428194.2016.1146948] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.6] [Reference Citation Analysis]
|
| 216 |
Robinson TM, O'Donnell PV, Fuchs EJ, Luznik L. Haploidentical bone marrow and stem cell transplantation: experience with post-transplantation cyclophosphamide. Semin Hematol 2016;53:90-7. [PMID: 27000732 DOI: 10.1053/j.seminhematol.2016.01.005] [Cited by in Crossref: 93] [Cited by in F6Publishing: 98] [Article Influence: 13.3] [Reference Citation Analysis]
|
| 217 |
Martin PS, Li S, Nikiforow S, Alyea EP, Antin JH, Armand P, Cutler CS, Ho VT, Kekre N, Koreth J, Luckey CJ, Ritz J, Soiffer RJ. Infused total nucleated cell dose is a better predictor of transplant outcomes than CD34+ cell number in reduced-intensity mobilized peripheral blood allogeneic hematopoietic cell transplantation. Haematologica. 2016;101:499-505. [PMID: 26768686 DOI: 10.3324/haematol.2015.134841] [Cited by in Crossref: 32] [Cited by in F6Publishing: 34] [Article Influence: 4.6] [Reference Citation Analysis]
|
| 218 |
Björklund AT, Clancy T, Goodridge JP, Béziat V, Schaffer M, Hovig E, Ljunggren HG, Ljungman PT, Malmberg KJ. Naive Donor NK Cell Repertoires Associated with Less Leukemia Relapse after Allogeneic Hematopoietic Stem Cell Transplantation. J Immunol 2016;196:1400-11. [PMID: 26746188 DOI: 10.4049/jimmunol.1501434] [Cited by in Crossref: 24] [Cited by in F6Publishing: 24] [Article Influence: 3.4] [Reference Citation Analysis]
|
| 219 |
Armand P, Kim HT, Sainvil MM, Lange PB, Giardino AA, Bachanova V, Devine SM, Waller EK, Jagirdar N, Herrera AF, Cutler C, Ho VT, Koreth J, Alyea EP, McAfee SL, Soiffer RJ, Chen YB, Antin JH. The addition of sirolimus to the graft-versus-host disease prophylaxis regimen in reduced intensity allogeneic stem cell transplantation for lymphoma: a multicentre randomized trial. Br J Haematol 2016;173:96-104. [PMID: 26729448 DOI: 10.1111/bjh.13931] [Cited by in Crossref: 43] [Cited by in F6Publishing: 46] [Article Influence: 6.1] [Reference Citation Analysis]
|
| 220 |
Scott BL, Sandmaier BM. The Evaluation and Counseling of Candidates for Hematopoietic Cell Transplantation. Thomas’ Hematopoietic Cell Transplantation 2016. [DOI: 10.1002/9781118416426.ch29] [Reference Citation Analysis]
|
| 221 |
Bashey A, Zhang X, Jackson K, Brown S, Ridgeway M, Solh M, Morris LE, Holland HK, Solomon SR. Comparison of Outcomes of Hematopoietic Cell Transplants from T-Replete Haploidentical Donors Using Post-Transplantation Cyclophosphamide with 10 of 10 HLA-A, -B, -C, -DRB1, and -DQB1 Allele-Matched Unrelated Donors and HLA-Identical Sibling Donors: A Multivariable Analysis Including Disease Risk Index. Biology of Blood and Marrow Transplantation 2016;22:125-33. [DOI: 10.1016/j.bbmt.2015.09.002] [Cited by in Crossref: 107] [Cited by in F6Publishing: 91] [Article Influence: 15.3] [Reference Citation Analysis]
|
| 222 |
Blaise D, Fürst S, Crocchiolo R, El-cheikh J, Granata A, Harbi S, Bouabdallah R, Devillier R, Bramanti S, Lemarie C, Picard C, Chabannon C, Weiller P, Faucher C, Mohty B, Vey N, Castagna L. Haploidentical T Cell–Replete Transplantation with Post-Transplantation Cyclophosphamide for Patients in or above the Sixth Decade of Age Compared with Allogeneic Hematopoietic Stem Cell Transplantation from an Human Leukocyte Antigen–Matched Related or Unrelated Donor. Biology of Blood and Marrow Transplantation 2016;22:119-24. [DOI: 10.1016/j.bbmt.2015.08.029] [Cited by in Crossref: 72] [Cited by in F6Publishing: 76] [Article Influence: 10.3] [Reference Citation Analysis]
|
| 223 |
Braamse AM, Yi JC, Visser OJ, Heymans MW, van Meijel B, Dekker J, Syrjala KL. Developing a Risk Prediction Model for Long-Term Physical and Psychological Functioning after Hematopoietic Cell Transplantation. Biol Blood Marrow Transplant. 2016;22:549-556. [PMID: 26685773 DOI: 10.1016/j.bbmt.2015.11.1102] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 1.4] [Reference Citation Analysis]
|
| 224 |
McCurdy SR, Fuchs EJ. Comparable Outcomes for Hematologic Malignancies after HLA-Haploidentical Transplantation with Posttransplantation Cyclophosphamide and HLA-Matched Transplantation. Adv Hematol 2015;2015:431923. [PMID: 26713094 DOI: 10.1155/2015/431923] [Cited by in Crossref: 17] [Cited by in F6Publishing: 17] [Article Influence: 2.1] [Reference Citation Analysis]
|
| 225 |
Atilla E, Ataca P, Ozyurek E, Erden I, Gurman G. Successful Bosutinib Experience in an Elderly Acute Lymphoblastic Leukemia Patient with Suspected Central Nervous System Involvement Transformed from Chronic Myeloid Leukemia. Case Rep Hematol 2015;2015:689423. [PMID: 26697241 DOI: 10.1155/2015/689423] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
|
| 226 |
Fuerst D, Mueller C, Beelen DW, Neuchel C, Tsamadou C, Schrezenmeier H, Mytilineos J. Time-dependent effects of clinical predictors in unrelated hematopoietic stem cell transplantation. Haematologica 2016;101:241-7. [PMID: 26611475 DOI: 10.3324/haematol.2015.130401] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 0.3] [Reference Citation Analysis]
|
| 227 |
Apperley J, Niederwieser D, Huang XJ, Nagler A, Fuchs E, Szer J, Kodera Y. Haploidentical Hematopoietic Stem Cell Transplantation: A Global Overview Comparing Asia, the European Union, and the United States. Biol Blood Marrow Transplant 2016;22:23-6. [PMID: 26551633 DOI: 10.1016/j.bbmt.2015.11.001] [Cited by in Crossref: 47] [Cited by in F6Publishing: 45] [Article Influence: 5.9] [Reference Citation Analysis]
|
| 228 |
Mo X, Zhang X, Xu L, Wang Y, Yan C, Chen H, Chen Y, Han W, Wang F, Wang J, Liu K, Huang X. Interferon-α: A Potentially Effective Treatment for Minimal Residual Disease in Acute Leukemia/Myelodysplastic Syndrome after Allogeneic Hematopoietic Stem Cell Transplantation. Biology of Blood and Marrow Transplantation 2015;21:1939-47. [DOI: 10.1016/j.bbmt.2015.06.014] [Cited by in Crossref: 45] [Cited by in F6Publishing: 46] [Article Influence: 5.6] [Reference Citation Analysis]
|
| 229 |
Showel M, Fuchs EJ. Recent developments in HLA-haploidentical transplantations. Best Pract Res Clin Haematol 2015;28:141-6. [PMID: 26590771 DOI: 10.1016/j.beha.2015.10.011] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.6] [Reference Citation Analysis]
|
| 230 |
Wood WA, Le-Rademacher J, Syrjala KL, Jim H, Jacobsen PB, Knight JM, Abidi MH, Wingard JR, Majhail NS, Geller NL, Rizzo JD, Fei M, Wu J, Horowitz MM, Lee SJ. Patient-reported physical functioning predicts the success of hematopoietic cell transplantation (BMT CTN 0902). Cancer 2016;122:91-8. [PMID: 26439325 DOI: 10.1002/cncr.29717] [Cited by in Crossref: 48] [Cited by in F6Publishing: 50] [Article Influence: 6.0] [Reference Citation Analysis]
|
| 231 |
Schneidawind D, Federmann B, Buechele C, Helwig A, Schmohl J, Vogel W, Faul C, Kanz L, Bethge WA. Reduced-intensity conditioning with fludarabine and busulfan for allogeneic hematopoietic cell transplantation in elderly or infirm patients with advanced myeloid malignancies. Ann Hematol 2016;95:115-24. [PMID: 26411736 DOI: 10.1007/s00277-015-2512-y] [Cited by in Crossref: 7] [Cited by in F6Publishing: 4] [Article Influence: 0.9] [Reference Citation Analysis]
|
| 232 |
Gaballa S, Palmisiano N, Alpdogan O, Carabasi M, Filicko-O'Hara J, Kasner M, Kraft WK, Leiby B, Martinez-Outschoorn U, O'Hara W, Pro B, Rudolph S, Sharma M, Wagner JL, Weiss M, Flomenberg N, Grosso D. A Two-Step Haploidentical Versus a Two-Step Matched Related Allogeneic Myeloablative Peripheral Blood Stem Cell Transplantation. Biol Blood Marrow Transplant 2016;22:141-8. [PMID: 26415558 DOI: 10.1016/j.bbmt.2015.09.017] [Cited by in Crossref: 24] [Cited by in F6Publishing: 24] [Article Influence: 3.0] [Reference Citation Analysis]
|
| 233 |
Teixeira GM, Bittencourt H, de Macedo AV, Martinho GH, Colosimo EA, Rezende SM. Assessing the Influence of Different Comorbidities Indexes on the Outcomes of Allogeneic Hematopoietic Stem Cell Transplantation in a Developing Country. PLoS One 2015;10:e0137390. [PMID: 26394228 DOI: 10.1371/journal.pone.0137390] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 234 |
Basquiera AL, Rivas MM, Remaggi G, Klein G, Milovic V, Foncuberta MC, Saba S, Milone JH, Arbelbide J, Jaimovich G, Rolón JM, Kusminsky G, García JJ, Prates MV. Allogeneic hematopoietic stem cell transplantation in adults with myelodysplastic syndrome: Experience of the Argentinean Group of Bone Marrow Transplantation (GATMO). Hematology 2016;21:162-9. [PMID: 26147089 DOI: 10.1179/1607845415Y.0000000028] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
|
| 235 |
Kekre N, Kim HT, Thanarajasingam G, Armand P, Antin JH, Cutler C, Nikiforow S, Ho VT, Koreth J, Alyea EP, Soiffer RJ. Efficacy of immune suppression tapering in treating relapse after reduced intensity allogeneic stem cell transplantation. Haematologica 2015;100:1222-7. [PMID: 26088931 DOI: 10.3324/haematol.2015.129650] [Cited by in Crossref: 16] [Cited by in F6Publishing: 16] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 236 |
Lin X, Lu ZG, Song CY, Huang YX, Guo KY, Deng L, Tu SF, He YZ, Xu JH, Long H, Wu BY. Long-term outcome of HLA-haploidentical hematopoietic stem cell transplantation without in vitro T-cell depletion based on an FBCA conditioning regimen for hematologic malignancies. Bone Marrow Transplant 2015;50:1092-7. [PMID: 25961770 DOI: 10.1038/bmt.2015.108] [Cited by in Crossref: 17] [Cited by in F6Publishing: 17] [Article Influence: 2.1] [Reference Citation Analysis]
|
| 237 |
McCurdy SR, Kanakry JA, Showel MM, Tsai HL, Bolaños-Meade J, Rosner GL, Kanakry CG, Perica K, Symons HJ, Brodsky RA, Gladstone DE, Huff CA, Pratz KW, Prince GT, Dezern AE, Gojo I, Matsui WH, Borrello I, McDevitt MA, Swinnen LJ, Smith BD, Levis MJ, Ambinder RF, Luznik L, Jones RJ, Fuchs EJ, Kasamon YL. Risk-stratified outcomes of nonmyeloablative HLA-haploidentical BMT with high-dose posttransplantation cyclophosphamide. Blood 2015;125:3024-31. [PMID: 25814532 DOI: 10.1182/blood-2015-01-623991] [Cited by in Crossref: 213] [Cited by in F6Publishing: 226] [Article Influence: 26.6] [Reference Citation Analysis]
|
| 238 |
Popat U, Mehta RS, Rezvani K, Fox P, Kondo K, Marin D, McNiece I, Oran B, Hosing C, Olson A, Parmar S, Shah N, Andreeff M, Kebriaei P, Kaur I, Yvon E, de Lima M, Cooper LJ, Tewari P, Champlin RE, Nieto Y, Andersson BS, Alousi A, Jones RB, Qazilbash MH, Bashir Q, Ciurea S, Ahmed S, Anderlini P, Bosque D, Bollard C, Molldrem JJ, Chen J, Rondon G, Thomas M, Miller L, Wolpe S, Simmons P, Robinson S, Zweidler-McKay PA, Shpall EJ. Enforced fucosylation of cord blood hematopoietic cells accelerates neutrophil and platelet engraftment after transplantation. Blood 2015;125:2885-92. [PMID: 25778529 DOI: 10.1182/blood-2015-01-607366] [Cited by in Crossref: 99] [Cited by in F6Publishing: 104] [Article Influence: 12.4] [Reference Citation Analysis]
|
| 239 |
El-Cheikh J, Crocchiolo R, Furst S, Bramanti S, Sarina B, Granata A, Vai A, Lemarie C, Faucher C, Mohty B, Harbi S, Bouabdallah R, Vey N, Santoro A, Chabannon C, Castagna L, Blaise D. Unrelated cord blood compared with haploidentical grafts in patients with hematological malignancies. Cancer 2015;121:1809-16. [PMID: 25649994 DOI: 10.1002/cncr.29271] [Cited by in Crossref: 26] [Cited by in F6Publishing: 30] [Article Influence: 3.3] [Reference Citation Analysis]
|
| 240 |
Au BK, Gooley TA, Armand P, Fang M, Madtes DK, Sorror ML, Boeckh MJ, Gibson CJ, Deeg HJ, Storb R, Appelbaum FR, Chien JW, Martin PJ. Reevaluation of the pretransplant assessment of mortality score after allogeneic hematopoietic transplantation. Biol Blood Marrow Transplant 2015;21:848-54. [PMID: 25644959 DOI: 10.1016/j.bbmt.2015.01.011] [Cited by in Crossref: 28] [Cited by in F6Publishing: 33] [Article Influence: 3.5] [Reference Citation Analysis]
|
| 241 |
Kim HT, Armand P, Frederick D, Andler E, Cutler C, Koreth J, Alyea EP 3rd, Antin JH, Soiffer RJ, Ritz J, Ho VT. Absolute lymphocyte count recovery after allogeneic hematopoietic stem cell transplantation predicts clinical outcome. Biol Blood Marrow Transplant 2015;21:873-80. [PMID: 25623931 DOI: 10.1016/j.bbmt.2015.01.019] [Cited by in Crossref: 42] [Cited by in F6Publishing: 37] [Article Influence: 5.3] [Reference Citation Analysis]
|
| 242 |
Federmann B, Faul C, Meisner C, Vogel W, Kanz L, Bethge WA. Influence of age on outcome after allogeneic hematopoietic cell transplantation: a single center study in patients aged ⩾60. Bone Marrow Transplant 2015;50:427-31. [DOI: 10.1038/bmt.2014.292] [Cited by in Crossref: 12] [Cited by in F6Publishing: 13] [Article Influence: 1.5] [Reference Citation Analysis]
|
| 243 |
Ofran Y, Lazarus HM, Rapoport AP, Rowe JM. Interpreting outcome data in hematopoietic cell transplantation for leukemia: tackling common biases. Bone Marrow Transplant 2015;50:324-33. [DOI: 10.1038/bmt.2014.270] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 0.5] [Reference Citation Analysis]
|
| 244 |
Lim AB, Roberts AW, Mason K, Bajel A, Szer J, Ritchie DS. Validating the Allogeneic Stem Cell Transplantation Disease Risk Index: Sample Size, Follow-up, and Local Data Are Important. Transplantation 2015;99:128-32. [DOI: 10.1097/tp.0000000000000257] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 1.3] [Reference Citation Analysis]
|
| 245 |
Muffly L. Patient selection for allogeneic hematopoietic cell transplantation (HCT): the evolution of HCT risk assessment. Curr Hematol Malig Rep 2015;10:28-34. [PMID: 25500987 DOI: 10.1007/s11899-014-0241-2] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
|
| 246 |
Spring L, Li S, Soiffer RJ, Antin JH, Alyea EP 3rd, Glotzbecker B. Risk factors for readmission after allogeneic hematopoietic stem cell transplantation and impact on overall survival. Biol Blood Marrow Transplant 2015;21:509-16. [PMID: 25482866 DOI: 10.1016/j.bbmt.2014.11.682] [Cited by in Crossref: 28] [Cited by in F6Publishing: 26] [Article Influence: 3.1] [Reference Citation Analysis]
|
| 247 |
Singh H, Nikiforow S, Li S, Ballen KK, Spitzer TR, Soiffer R, Antin JH, Cutler C, Chen YB. Outcomes and management strategies for graft failure after umbilical cord blood transplantation. Am J Hematol 2014;89:1097-101. [PMID: 25195500 DOI: 10.1002/ajh.23845] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 1.3] [Reference Citation Analysis]
|
| 248 |
Brammer JE, Stentz A, Gajewski J, Curtin P, Hayes-Lattin B, Kovacsovics T, Leis JF, Meyers G, Nemecek E, Subbiah N, Frires R, Palmbach G, Avraham GP, Slater S, Maziarz RT. Nonmyeloablative allogeneic hematopoietic stem cell transplant for the treatment of patients with hematologic malignancies using busulfan, fludarabine, and total body irradiation conditioning is effective in an elderly and infirm population. Biol Blood Marrow Transplant 2015;21:89-96. [PMID: 25445641 DOI: 10.1016/j.bbmt.2014.09.024] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 249 |
Majhail NS, Jagasia M. Referral to transplant center for hematopoietic cell transplantation. Hematol Oncol Clin North Am 2014;28:1201-13. [PMID: 25459188 DOI: 10.1016/j.hoc.2014.08.007] [Cited by in Crossref: 6] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
|
| 250 |
Beauverd Y, Roosnek E, Tirefort Y, Nagy-hulliger M, Bernimoulin M, Tsopra O, Ansari M, Dantin C, Casini A, Grandjean A, Chigrinova E, Masouridi-levrat S, Chalandon Y. Validation of the Disease Risk Index for Outcome of Patients Undergoing Allogeneic Hematopoietic Stem Cell Transplantation after T Cell Depletion. Biology of Blood and Marrow Transplantation 2014;20:1322-8. [DOI: 10.1016/j.bbmt.2014.04.023] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 1.2] [Reference Citation Analysis]
|
| 251 |
Ostendorf BN, Blau O, Uharek L, Blau IW, Penack O. Association between low uric acid levels and acute graft-versus-host disease. Ann Hematol 2015;94:139-44. [DOI: 10.1007/s00277-014-2180-3] [Cited by in Crossref: 9] [Cited by in F6Publishing: 11] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 252 |
Sorror ML, Storb RF, Sandmaier BM, Maziarz RT, Pulsipher MA, Maris MB, Bhatia S, Ostronoff F, Deeg HJ, Syrjala KL, Estey E, Maloney DG, Appelbaum FR, Martin PJ, Storer BE. Comorbidity-age index: a clinical measure of biologic age before allogeneic hematopoietic cell transplantation. J Clin Oncol 2014;32:3249-56. [PMID: 25154831 DOI: 10.1200/JCO.2013.53.8157] [Cited by in Crossref: 280] [Cited by in F6Publishing: 301] [Article Influence: 31.1] [Reference Citation Analysis]
|
| 253 |
Khera N, Chang YH, Slack J, Fauble V, Leis JF, Noel P, Sproat L, Palmer J, Adams R, Fitch T, Northfelt D, Guy M, Tilburt J, Mikhael J. Impact of race and ethnicity on outcomes and health care utilization after allogeneic hematopoietic cell transplantation. Leuk Lymphoma 2015;56:987-92. [PMID: 25012944 DOI: 10.3109/10428194.2014.941834] [Cited by in Crossref: 10] [Cited by in F6Publishing: 12] [Article Influence: 1.1] [Reference Citation Analysis]
|
| 254 |
Guillaume T, Porcheron S, Audat F, Bancillon N, Berceanu A, Charbonnier A, Dulery R, Edy N, El Cheikh J, Hermet E, Maurer N, Paul F, Konopacki-potet J, Turlure P, Wallart A, Boulanger F, Dhédin N, Suarez F, Yakoub-agha I. Recommandations de la SFGM-TC concernant l’injection prophylactique, préemptive et curative des lymphocytes du donneur (DLI) après allogreffe de cellules souches hématopoïétiques. Pathologie Biologie 2014;62:193-6. [DOI: 10.1016/j.patbio.2014.05.011] [Cited by in Crossref: 12] [Cited by in F6Publishing: 13] [Article Influence: 1.3] [Reference Citation Analysis]
|
| 255 |
Abedin S, Peres E, Levine JE, Choi S, Yanik G, Couriel DR. Double umbilical cord blood transplantation after novel myeloablative conditioning using a regimen of fludarabine, busulfan, and total lymphoid irradiation. Biol Blood Marrow Transplant 2014;20:2062-6. [PMID: 25046834 DOI: 10.1016/j.bbmt.2014.07.014] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 0.9] [Reference Citation Analysis]
|
| 256 |
Raiola AM, Dominietto A, di Grazia C, Lamparelli T, Gualandi F, Ibatici A, Bregante S, Van Lint MT, Varaldo R, Ghiso A, Gobbi M, Carella AM, Signori A, Galaverna F, Bacigalupo A. Unmanipulated haploidentical transplants compared with other alternative donors and matched sibling grafts. Biol Blood Marrow Transplant 2014;20:1573-9. [PMID: 24910379 DOI: 10.1016/j.bbmt.2014.05.029] [Cited by in Crossref: 213] [Cited by in F6Publishing: 230] [Article Influence: 23.7] [Reference Citation Analysis]
|
| 257 |
Koreth J, Kim HT, Nikiforow S, Milford EL, Armand P, Cutler C, Glotzbecker B, Ho VT, Antin JH, Soiffer RJ, Ritz J, Alyea EP 3rd. Donor chimerism early after reduced-intensity conditioning hematopoietic stem cell transplantation predicts relapse and survival. Biol Blood Marrow Transplant 2014;20:1516-21. [PMID: 24907627 DOI: 10.1016/j.bbmt.2014.05.025] [Cited by in Crossref: 36] [Cited by in F6Publishing: 37] [Article Influence: 4.0] [Reference Citation Analysis]
|
| 258 |
Peccatori J, Forcina A, Clerici D, Crocchiolo R, Vago L, Stanghellini MT, Noviello M, Messina C, Crotta A, Assanelli A, Marktel S, Olek S, Mastaglio S, Giglio F, Crucitti L, Lorusso A, Guggiari E, Lunghi F, Carrabba M, Tassara M, Battaglia M, Ferraro A, Carbone MR, Oliveira G, Roncarolo MG, Rossini S, Bernardi M, Corti C, Marcatti M, Patriarca F, Zecca M, Locatelli F, Bordignon C, Fleischhauer K, Bondanza A, Bonini C, Ciceri F. Sirolimus-based graft-versus-host disease prophylaxis promotes the in vivo expansion of regulatory T cells and permits peripheral blood stem cell transplantation from haploidentical donors. Leukemia 2015;29:396-405. [PMID: 24897508 DOI: 10.1038/leu.2014.180] [Cited by in Crossref: 87] [Cited by in F6Publishing: 94] [Article Influence: 9.7] [Reference Citation Analysis]
|
| 259 |
Kim HT, Frederick D, Armand P, Andler E, Kao G, Cutler C, Koreth J, Alyea EP 3rd, Antin JH, Soiffer RJ, Ritz J, Ho VT. White blood cell recovery after allogeneic hematopoietic cell transplantation predicts clinical outcome. Am J Hematol 2014;89:591-7. [PMID: 24549932 DOI: 10.1002/ajh.23695] [Cited by in Crossref: 15] [Cited by in F6Publishing: 16] [Article Influence: 1.7] [Reference Citation Analysis]
|
| 260 |
Ganly P, Cole S, Trengrove A, Butler A. Outcomes of allogeneic haemopoietic stem cell transplants at a small New Zealand centre: does size matter? Intern Med J 2014;44:683-9. [PMID: 24750295 DOI: 10.1111/imj.12456] [Reference Citation Analysis]
|
| 261 |
Armand P, Kim HT, Logan BR, Wang Z, Alyea EP, Kalaycio ME, Maziarz RT, Antin JH, Soiffer RJ, Weisdorf DJ, Rizzo JD, Horowitz MM, Saber W. Validation and refinement of the Disease Risk Index for allogeneic stem cell transplantation. Blood 2014;123:3664-71. [PMID: 24744269 DOI: 10.1182/blood-2014-01-552984] [Cited by in Crossref: 578] [Cited by in F6Publishing: 600] [Article Influence: 64.2] [Reference Citation Analysis]
|
| 262 |
Jeljeli M, Guérin-El Khourouj V, Porcher R, Fahd M, Leveillé S, Yakouben K, Ouachée-Chardin M, LeGoff J, Cordeiro DJ, Pédron B, Baruchel A, Dalle JH, Sterkers G. Relationship between cytomegalovirus (CMV) reactivation, CMV-driven immunity, overall immune recovery and graft-versus-leukaemia effect in children. Br J Haematol 2014;166:229-39. [PMID: 24702221 DOI: 10.1111/bjh.12875] [Cited by in Crossref: 30] [Cited by in F6Publishing: 33] [Article Influence: 3.3] [Reference Citation Analysis]
|
| 263 |
Devillier R, Fürst S, Crocchiolo R, El-Cheikh J, Castagna L, Harbi S, Granata A, D'Incan E, Coso D, Chabannon C, Picard C, Etienne A, Calmels B, Schiano JM, Lemarie C, Stoppa AM, Bouabdallah R, Vey N, Blaise D. A conditioning platform based on fludarabine, busulfan, and 2 days of rabbit antithymocyte globulin results in promising results in patients undergoing allogeneic transplantation from both matched and mismatched unrelated donor. Am J Hematol 2014;89:83-7. [PMID: 24108528 DOI: 10.1002/ajh.23592] [Cited by in Crossref: 20] [Cited by in F6Publishing: 22] [Article Influence: 2.2] [Reference Citation Analysis]
|
| 264 |
Bevans MF, Mitchell SA, Barrett JA, Bishop MR, Childs R, Fowler D, Krumlauf M, Prince P, Shelburne N, Wehrlen L, Yang L. Symptom distress predicts long-term health and well-being in allogeneic stem cell transplantation survivors. Biol Blood Marrow Transplant 2014;20:387-95. [PMID: 24355521 DOI: 10.1016/j.bbmt.2013.12.001] [Cited by in Crossref: 33] [Cited by in F6Publishing: 34] [Article Influence: 3.3] [Reference Citation Analysis]
|
| 265 |
Devillier R, Fürst S, El-Cheikh J, Castagna L, Harbi S, Granata A, Crocchiolo R, Oudin C, Mohty B, Bouabdallah R, Chabannon C, Stoppa AM, Charbonnier A, Broussais-Guillaumot F, Calmels B, Lemarie C, Rey J, Vey N, Blaise D. Antithymocyte globulin in reduced-intensity conditioning regimen allows a high disease-free survival exempt of long-term chronic graft-versus-host disease. Biol Blood Marrow Transplant 2014;20:370-4. [PMID: 24315846 DOI: 10.1016/j.bbmt.2013.11.030] [Cited by in Crossref: 35] [Cited by in F6Publishing: 35] [Article Influence: 3.5] [Reference Citation Analysis]
|
| 266 |
Servais S, Porcher R, Xhaard A, Robin M, Masson E, Larghero J, Ribaud P, Dhedin N, Abbes S, Sicre F, Socié G, Peffault de Latour R. Pre-transplant prognostic factors of long-term survival after allogeneic peripheral blood stem cell transplantation with matched related/unrelated donors. Haematologica 2014;99:519-26. [PMID: 24241489 DOI: 10.3324/haematol.2013.089979] [Cited by in Crossref: 27] [Cited by in F6Publishing: 30] [Article Influence: 2.7] [Reference Citation Analysis]
|
| 267 |
Goy A. Mantle cell lymphoma: continuously improving the odds! Expert Opinion on Orphan Drugs 2013;1:1001-18. [DOI: 10.1517/21678707.2013.854700] [Reference Citation Analysis]
|
| 268 |
Barba P, Martino R, Pérez-Simón JA, Fernández-Avilés F, Castillo N, Piñana JL, López-Anglada L, Rovira M, Bosch F, Carreras E, Corral LL, Sierra J, Valcárcel D. Combination of the Hematopoietic Cell Transplantation Comorbidity Index and the European Group for Blood and Marrow Transplantation score allows a better stratification of high-risk patients undergoing reduced-toxicity allogeneic hematopoietic cell transplantation. Biol Blood Marrow Transplant 2014;20:66-72. [PMID: 24141006 DOI: 10.1016/j.bbmt.2013.10.011] [Cited by in Crossref: 35] [Cited by in F6Publishing: 37] [Article Influence: 3.5] [Reference Citation Analysis]
|
| 269 |
Thanarajasingam G, Kim HT, Cutler C, Ho VT, Koreth J, Alyea EP, Antin JH, Soiffer RJ, Armand P. Outcome and prognostic factors for patients who relapse after allogeneic hematopoietic stem cell transplantation. Biol Blood Marrow Transplant 2013;19:1713-8. [PMID: 24076323 DOI: 10.1016/j.bbmt.2013.09.011] [Cited by in Crossref: 56] [Cited by in F6Publishing: 56] [Article Influence: 5.6] [Reference Citation Analysis]
|
| 270 |
Slack JL, Dueck AC, Fauble VD, Sproat LO, Reeder CB, Noel P, Khera N, Betcher JA, Klein JL, Leis JF, Adams RH. Reduced Toxicity Conditioning and Allogeneic Stem Cell Transplantation in Adults Using Fludarabine, Carmustine, Melphalan, and Antithymocyte Globulin: Outcomes Depend on Disease Risk Index but Not Age, Comorbidity Score, Donor Type, or Human Leukocyte Antigen Mismatch. Biology of Blood and Marrow Transplantation 2013;19:1167-74. [DOI: 10.1016/j.bbmt.2013.05.001] [Cited by in Crossref: 13] [Cited by in F6Publishing: 14] [Article Influence: 1.3] [Reference Citation Analysis]
|
| 271 |
Grunwald MR. Allogeneic hematopoietic cell transplantation in septuagenarians. Biol Blood Marrow Transplant 2013;19:1276-8. [PMID: 23871779 DOI: 10.1016/j.bbmt.2013.07.012] [Reference Citation Analysis]
|
| 272 |
Cutler C, Kim HT, Bindra B, Sarantopoulos S, Ho VT, Chen YB, Rosenblatt J, McDonough S, Watanaboonyongcharoen P, Armand P, Koreth J, Glotzbecker B, Alyea E, Blazar BR, Soiffer RJ, Ritz J, Antin JH. Rituximab prophylaxis prevents corticosteroid-requiring chronic GVHD after allogeneic peripheral blood stem cell transplantation: results of a phase 2 trial. Blood 2013;122:1510-7. [PMID: 23861248 DOI: 10.1182/blood-2013-04-495895] [Cited by in Crossref: 88] [Cited by in F6Publishing: 94] [Article Influence: 8.8] [Reference Citation Analysis]
|
| 273 |
Kleber M, Ihorst G, Gross B, Koch B, Reinhardt H, Wäsch R, Engelhardt M. Validation of the Freiburg Comorbidity Index in 466 multiple myeloma patients and combination with the international staging system are highly predictive for outcome. Clin Lymphoma Myeloma Leuk 2013;13:541-51. [PMID: 23810244 DOI: 10.1016/j.clml.2013.03.013] [Cited by in Crossref: 54] [Cited by in F6Publishing: 65] [Article Influence: 5.4] [Reference Citation Analysis]
|
| 274 |
Brunner AM, Kim HT, Coughlin E, Alyea EP 3rd, Armand P, Ballen KK, Cutler C, Dey BR, Glotzbecker B, Koreth J, McAfee SL, Spitzer TR, Soiffer RJ, Antin JH, Ho VT, Chen YB. Outcomes in patients age 70 or older undergoing allogeneic hematopoietic stem cell transplantation for hematologic malignancies. Biol Blood Marrow Transplant 2013;19:1374-80. [PMID: 23791626 DOI: 10.1016/j.bbmt.2013.06.008] [Cited by in Crossref: 60] [Cited by in F6Publishing: 66] [Article Influence: 6.0] [Reference Citation Analysis]
|
| 275 |
Wood WA, Deal AM, Reeve BB, Abernethy AP, Basch E, Mitchell SA, Shatten C, Hie Kim Y, Whitley J, Serody JS, Shea T, Battaglini C. Cardiopulmonary fitness in patients undergoing hematopoietic SCT: a pilot study. Bone Marrow Transplant 2013;48:1342-9. [PMID: 23584437 DOI: 10.1038/bmt.2013.58] [Cited by in Crossref: 61] [Cited by in F6Publishing: 63] [Article Influence: 6.1] [Reference Citation Analysis]
|
| 276 |
Lazarus HM, Litzow MR. AML cytogenetics: the complex just got simpler. Blood 2012;120:2357-8. [PMID: 22996657 DOI: 10.1182/blood-2012-08-448555] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.5] [Reference Citation Analysis]
|
| 277 |
Castagna L, Boubdallah R, Furst S, Coso D, El Cheikh J, Faucher C, Crocchiolo R, Granata A, Chabannon C, Lemarié C, Calmels B, Boher JM, Mohty M, Blaise D. Disease status is a more reliable predictive factor than histology in lymphoma patients after reduced-intensity conditioning regimen and allo-SCT. Bone Marrow Transplant 2013;48:794-8. [DOI: 10.1038/bmt.2012.225] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 0.5] [Reference Citation Analysis]
|
